{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:59:41Z","timestamp":1790193581614,"version":"4.1.0"},"reference-count":266,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"DOI":"10.1007\/s00467-026-07537-7","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:48:05Z","timestamp":1790146085000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["IPNA clinical practice recommendations for the management of aHUS and secondary TMA in children"],"prefix":"10.1007","author":[{"given":"Magdalena","family":"Riedl Khursigara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura F.","family":"Alconcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Alhasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atif","family":"Awan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Bagga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Admani","family":"Bashir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilzete Liberato","family":"Bresolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula A.","family":"Coccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Durkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry A.","family":"Greenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Gyung","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Haffner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumoto","family":"Iijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kavanagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Khandelwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Loos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison Lap-tak","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mignon","family":"McCulloch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian Monteiro Pereira","family":"Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Pape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupesh","family":"Raina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesham","family":"Safouh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rezan","family":"Topaloglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole C. A. J.","family":"van de Kar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Van de Walle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4168-3277","authenticated-orcid":false,"given":"Christoph","family":"Licht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"7537_CR1","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12882-015-0195-1","volume":"16","author":"C Licht","year":"2015","unstructured":"Licht C, Ardissino G, Ariceta G, Cohen D, Cole JA, Gasteyger C, Greenbaum LA, Johnson S, Ogawa M, Schaefer F, Vande Walle J, Fremeaux-Bacchi V (2015) The global aHUS registry: methodology and initial patient characteristics. BMC Nephrol 16:207","journal-title":"BMC Nephrol"},{"key":"7537_CR2","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1056\/NEJMra1312353","volume":"371","author":"JN George","year":"2014","unstructured":"George JN, Nester CM (2014) Syndromes of thrombotic microangiopathy. N Engl J Med 371:654\u2013666","journal-title":"N Engl J Med"},{"key":"7537_CR3","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.imbio.2011.07.028","volume":"217","author":"H Kerr","year":"2012","unstructured":"Kerr H, Richards A (2012) Complement-mediated injury and protection of endothelium: lessons from atypical haemolytic uraemic syndrome. Immunobiology 217:195\u2013203","journal-title":"Immunobiology"},{"key":"7537_CR4","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.2215\/CJN.02210310","volume":"5","author":"M Noris","year":"2010","unstructured":"Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G (2010) Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 5:1844\u20131859","journal-title":"Clin J Am Soc Nephrol"},{"key":"7537_CR5","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.semnephrol.2013.08.003","volume":"33","author":"D Kavanagh","year":"2013","unstructured":"Kavanagh D, Goodship TH, Richards A (2013) Atypical hemolytic uremic syndrome. Semin Nephrol 33:508\u2013530","journal-title":"Semin Nephrol"},{"key":"7537_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01282","volume":"10","author":"M Puraswani","year":"2019","unstructured":"Puraswani M, Khandelwal P, Saini H, Saini S, Gurjar BS, Sinha A, Shende RP, Maiti TK, Singh AK, Kanga U, Ali U, Agarwal I, Anand K, Prasad N, Rajendran P, Sinha R, Vasudevan A, Saxena A, Agarwal S, Bagga A (2019) Clinical and immunological profile of anti-factor H antibody associated atypical hemolytic uremic syndrome: a nationwide database. Front Immunol 10:1282","journal-title":"Front Immunol"},{"key":"7537_CR7","doi-asserted-by":"crossref","unstructured":"Schaefer F, Ardissino G, Ariceta G, Fakhouri F, Scully M, Isbel N, Lommele A, Kupelian V, Gasteyger C, Greenbaum LA, Johnson S, Ogawa M, Licht C, Vande Walle J, Fremeaux-Bacchi V, Global aHUS Registry (2018) Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome. Kidney Int 94:408\u2013418","DOI":"10.1016\/j.kint.2018.02.029"},{"key":"7537_CR8","doi-asserted-by":"crossref","unstructured":"Glover EK, Smith-Jackson K, Brocklebank V, Wilson V, Walsh PR, Montgomery EK, Wong EKS, Johnson S, Malina M, Kavanagh D, Sheerin NS,\u00a0UK aHUS Transplant Consortium (2023) Assessing the impact of prophylactic eculizumab on renal graft survival in atypical hemolytic uremic syndrome. Transplantation 107:994\u20131003","DOI":"10.1097\/TP.0000000000004355"},{"key":"7537_CR9","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2215\/CJN.04760512","volume":"8","author":"V Fremeaux-Bacchi","year":"2013","unstructured":"Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaime F, Dragon-Durey MA, Ngo S, Moulin B, Servais A, Provot F, Rostaing L, Burtey S, Niaudet P, Deschenes G, Lebranchu Y, Zuber J, Loirat C (2013) Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 8:554\u2013562","journal-title":"Clin J Am Soc Nephrol"},{"key":"7537_CR10","doi-asserted-by":"crossref","unstructured":"Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, Mele C, Bresin E, Cassis L, Gamba S, Porrati F, Bucchioni S, Monteferrante G, Fang CJ, Liszewski MK, Kavanagh D, Atkinson JP, Remuzzi G,\u00a0International Registry of Recurrent and Familial HUS\/TTP (2006) Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 108:1267\u20131279","DOI":"10.1182\/blood-2005-10-007252"},{"key":"7537_CR11","doi-asserted-by":"crossref","unstructured":"Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, Macher MA, Niaudet P, Guest G, Boudailliez B, Bouissou F, Deschenes G, Gie S, Tsimaratos M, Fischbach M, Morin D, Nivet H, Alberti C, Loirat C, French Society of Pediatric Nephrology (2007) Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 18:2392\u20132400","DOI":"10.1681\/ASN.2006080811"},{"key":"7537_CR12","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1111\/j.1600-6143.2007.01888.x","volume":"7","author":"V Fremeaux-Bacchi","year":"2007","unstructured":"Fremeaux-Bacchi V, Arzouk N, Ferlicot S, Charpentier B, Snanoudj R, Durrbach A (2007) Recurrence of HUS due to CD46\/MCP mutation after renal transplantation: a role for endothelial microchimerism. Am J Transplant 7:2047\u20132051","journal-title":"Am J Transplant"},{"key":"7537_CR13","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1182\/blood-2007-04-084533","volume":"111","author":"CJ Fang","year":"2008","unstructured":"Fang CJ, Fremeaux-Bacchi V, Liszewski MK, Pianetti G, Noris M, Goodship TH, Atkinson JP (2008) Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. Blood 111:624\u2013632","journal-title":"Blood"},{"key":"7537_CR14","doi-asserted-by":"crossref","unstructured":"Fremeaux-Bacchi V, Miller EC, Liszewski MK, Strain L, Blouin J, Brown AL, Moghal N, Kaplan BS, Weiss RA, Lhotta K, Kapur G, Mattoo T, Nivet H, Wong W, Gie S, Hurault de Ligny B, Fischbach M, Gupta R, Hauhart R, ..., Atkinson JP (2008) Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 112:4948\u20134952","DOI":"10.1182\/blood-2008-01-133702"},{"key":"7537_CR15","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1093\/ndt\/gfp166","volume":"24","author":"T Kwon","year":"2009","unstructured":"Kwon T, Belot A, Ranchin B, Baudouin V, Fremeaux-Bacchi V, Dragon-Durey MA, Cochat P, Loirat C (2009) Varicella as a trigger of atypical haemolytic uraemic syndrome associated with complement dysfunction: two cases. Nephrol Dial Transplant 24:2752\u20132754","journal-title":"Nephrol Dial Transplant"},{"key":"7537_CR16","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1203\/PDR.0b013e3181b1bd4a","volume":"66","author":"BH Lee","year":"2009","unstructured":"Lee BH, Kwak SH, Shin JI, Lee SH, Choi HJ, Kang HG, Ha IS, Lee JS, Dragon-Durey MA, Choi Y, Cheong HI (2009) Atypical hemolytic uremic syndrome associated with complement factor H autoantibodies and CFHR1\/CFHR3 deficiency. Pediatr Res 66:336\u2013340","journal-title":"Pediatr Res"},{"key":"7537_CR17","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1681\/ASN.2010030315","volume":"21","author":"MA Dragon-Durey","year":"2010","unstructured":"Dragon-Durey MA, Sethi SK, Bagga A, Blanc C, Blouin J, Ranchin B, Andre JL, Takagi N, Cheong HI, Hari P, Le Quintrec M, Niaudet P, Loirat C, Fridman WH, Fremeaux-Bacchi V (2010) Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol 21:2180\u20132187","journal-title":"J Am Soc Nephrol"},{"key":"7537_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00467-010-1690-z","volume":"26","author":"U Allen","year":"2011","unstructured":"Allen U, Licht C (2011) Pandemic H1N1 influenza A infection and (atypical) HUS\u2013more than just another trigger? Pediatr Nephrol 26:3\u20135","journal-title":"Pediatr Nephrol"},{"key":"7537_CR19","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1182\/blood.2022017860","volume":"141","author":"F Fakhouri","year":"2023","unstructured":"Fakhouri F, Schwotzer N, Fremeaux-Bacchi V (2023) How I diagnose and treat atypical hemolytic uremic syndrome. Blood 141:984\u2013995","journal-title":"Blood"},{"key":"7537_CR20","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1159\/000497822","volume":"142","author":"R Topaloglu","year":"2019","unstructured":"Topaloglu R, Inozu M, Gulhan B, Gurbuz B, Talim B, Coskun T (2019) Do not miss rare and treatable cause of early-onset hemolytic uremic syndrome: cobalamin C deficiency. Nephron 142:258\u2013263","journal-title":"Nephron"},{"key":"7537_CR21","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/j.kint.2020.01.045","volume":"97","author":"V Brocklebank","year":"2020","unstructured":"Brocklebank V, Kumar G, Howie AJ, Chandar J, Milford DV, Craze J, Evans J, Finlay E, Freundlich M, Gale DP, Inward C, Mraz M, Jones C, Wong W, Marks SD, Connolly J, Corner BM, Smith-Jackson K, Walsh PR, Kavanagh D (2020) Long-term outcomes and response to treatment in diacylglycerol kinase epsilon nephropathy. Kidney Int 97:1260\u20131274","journal-title":"Kidney Int"},{"key":"7537_CR22","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1182\/blood.2022018833","volume":"142","author":"V Brocklebank","year":"2023","unstructured":"Brocklebank V, Walsh PR, Smith-Jackson K, Hallam TM, Marchbank KJ, Wilson V, Bigirumurame T, Dutt T, Montgomery EK, Malina M, Wong EKS, Johnson S, Sheerin NS, Kavanagh D (2023) Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort study. Blood 142:1371\u20131386","journal-title":"Blood"},{"key":"7537_CR23","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1055\/s-0034-1376153","volume":"40","author":"M Riedl","year":"2014","unstructured":"Riedl M, Fakhouri F, Le Quintrec M, Noone DG, Jungraithmayr TC, Fremeaux-Bacchi V, Licht C (2014) Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches. Semin Thromb Hemost 40:444\u2013464","journal-title":"Semin Thromb Hemost"},{"key":"7537_CR24","first-page":"S0085","volume":"26","author":"AL Ma","year":"2026","unstructured":"Ma AL, Alconcher L, Coccia P, Wong JW, Kusche-Vihrog K, Licht C (2026) Secondary Thrombotic Microangiopathy (TMA) in children - a central role for the glycocalyx. Kidney Int 26:S0085","journal-title":"Kidney Int"},{"key":"7537_CR25","doi-asserted-by":"crossref","unstructured":"Ariceta G, Dixon BP, Kim SH, Kapur G, Mauch T, Ortiz S, Vallee M, Denker AE, Kang HG, Greenbaum LA, 312 Study Group (2021) The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment. Kidney Int 100:225\u2013237","DOI":"10.1016\/j.kint.2020.10.046"},{"key":"7537_CR26","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1182\/blood-2021-145040","volume":"138","author":"BP Dixon","year":"2021","unstructured":"Dixon BP, Madris-Aris AD, Adams B, Kavanagh D, Kang HG, Wang J, Garlo K, Tanaka K, Greenbaum L, Ogawa M, Heyne N, Kim SH, Cataland S, Yoon S-S, Miyakawa Y, Luque Y, Muff-Luett M (2021) Two-year efficacy and safety of ravulizumab in adults and children with atypical hemolytic uremic syndrome (aHUS): analysis of two phase 3 studies. Blood 138:769\u2013769","journal-title":"Blood"},{"key":"7537_CR27","first-page":"1379","volume":"369","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Loirat C (2013) Eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 369:1379\u20131380","journal-title":"N Engl J Med"},{"key":"7537_CR28","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ki.2014.423","volume":"87","author":"C Licht","year":"2015","unstructured":"Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, Delmas Y, Douglas K, Furman RR, Gaber OA, Goodship T, Herthelius M, Hourmant M, Legendre CM, Remuzzi G, Sheerin N, Trivelli A, Loirat C (2015) Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 87:1061\u20131073","journal-title":"Kidney Int"},{"key":"7537_CR29","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","volume":"89","author":"LA Greenbaum","year":"2016","unstructured":"Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, Lieberman KV, Maringhini S, Pape L, Rees L, van de Kar NC, Vande Walle J, Ogawa M, Bedrosian CL, Licht C (2016) Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int 89:701\u2013711","journal-title":"Kidney Int"},{"key":"7537_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41390-024-03771-7","author":"K Doshi","year":"2024","unstructured":"Doshi K, Yusuf A, Licht C, Boyer O, Nester C, Murra A, Sharma P, Sethi S, Raina R (2024) Extrarenal manifestations of atypical hemolytic uremic syndrome: a systematic review and meta-analysis. Pediatr Res. https:\/\/doi.org\/10.1038\/s41390-024-03771-7","journal-title":"Pediatr Res"},{"key":"7537_CR31","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s00467-018-4039-7","volume":"34","author":"C Formeck","year":"2019","unstructured":"Formeck C, Swiatecka-Urban A (2019) Extra-renal manifestations of atypical hemolytic uremic syndrome. Pediatr Nephrol 34:1337\u20131348","journal-title":"Pediatr Nephrol"},{"key":"7537_CR32","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12882-019-1314-1","volume":"20","author":"J Menne","year":"2019","unstructured":"Menne J, Delmas Y, Fakhouri F, Licht C, Lommele A, Minetti EE, Provot F, Rondeau E, Sheerin NS, Wang J, Weekers LE, Greenbaum LA (2019) Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study. BMC Nephrol 20:125","journal-title":"BMC Nephrol"},{"key":"7537_CR33","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","volume":"68","author":"F Fakhouri","year":"2016","unstructured":"Fakhouri F, Hourmant M, Campistol JM, Cataland SR, Espinosa M, Gaber AO, Menne J, Minetti EE, Provot F, Rondeau E, Ruggenenti P, Weekers LE, Ogawa M, Bedrosian CL, Legendre CM (2016) Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial. Am J Kidney Dis 68:84\u201393","journal-title":"Am J Kidney Dis"},{"key":"7537_CR34","doi-asserted-by":"crossref","unstructured":"Siedlecki AM, Isbel N, Vande Walle J, James Eggleston J, Cohen DJ, Global aHUS Registry (2019) Eculizumab use for kidney transplantation in patients with a diagnosis of atypical hemolytic uremic syndrome. Kidney Int Rep 4:434\u2013446","DOI":"10.1016\/j.ekir.2018.11.010"},{"key":"7537_CR35","doi-asserted-by":"crossref","unstructured":"Duineveld C, Bouwmeester RN, Wijnsma KL, Bemelman FJ, van der Heijden JW, Berger SP, van den Heuvel L, van de Kar N, Wetzels JFM, Dutch aHUS Working Group (2023) Eculizumab rescue therapy in patients with recurrent atypical hemolytic uremic syndrome after kidney transplantation. Kidney Int Rep 8:715\u2013726","DOI":"10.1016\/j.ekir.2023.01.016"},{"key":"7537_CR36","doi-asserted-by":"crossref","unstructured":"Nishimura J, Yamamoto M, Hayashi S, Ohyashiki K, Ando K, Brodsky AL, Noji H, Kitamura K, Eto T, Takahashi T, Masuko M, Matsumoto T, Wano Y, Shichishima T, Shibayama H, Hase M, Li L, Johnson K, Lazarowski A, ..., Kanakura Y (2014) Genetic variants in C5 and poor response to eculizumab. N Engl J Med 370:632\u2013639","DOI":"10.1056\/NEJMoa1311084"},{"key":"7537_CR37","doi-asserted-by":"crossref","unstructured":"Bagga A, Khandelwal P, Mishra K, Thergaonkar R, Vasudevan A, Sharma J, Patnaik SK, Sinha A, Sethi S, Hari P, Dragon-Durey MA, Indian Society of Pediatric Nephrology (2019) Hemolytic uremic syndrome in a developing country: Consensus guidelines. Pediatr Nephrol 34:1465\u20131482","DOI":"10.1007\/s00467-019-04233-7"},{"key":"7537_CR38","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.kint.2024.05.021","volume":"106","author":"CM Nester","year":"2024","unstructured":"Nester CM, Feldman DL, Burwick R, Cataland S, Chaturvedi S, Cook HT, Cuker A, Dixon BP, Fakhouri F, Hingorani SR, Java A, van de Kar N, Kavanagh D, Leung N, Licht C, Noris M, O\u2019Shaughnessy MM, Parikh SV, Peyandi F, Vivarelli M (2024) An expert discussion on the atypical hemolytic uremic syndrome nomenclature-identifying a road map to precision: a report of a National Kidney Foundation Working Group. Kidney Int 106:326\u2013336","journal-title":"Kidney Int"},{"key":"7537_CR39","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jclinepi.2010.09.012","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, Alderson P, Glasziou P, Falck-Ytter Y, Schunemann HJ (2011) GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol 64:395\u2013400","journal-title":"J Clin Epidemiol"},{"key":"7537_CR40","doi-asserted-by":"crossref","unstructured":"Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, Coppo R, Emma F, Johnson S, Karpman D, Landau D, Langman CB, Lapeyraque AL, Licht C, Nester C, Pecoraro C, Riedl M, van de Kar NC, Van de Walle J, ..., International HUS (2016) An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 31:15\u201339","DOI":"10.1007\/s00467-015-3076-8"},{"key":"7537_CR41","doi-asserted-by":"publisher","first-page":"116","DOI":"10.5662\/wjm.v11.i4.116","volume":"11","author":"P Nasa","year":"2021","unstructured":"Nasa P, Jain R, Juneja D (2021) Delphi methodology in healthcare research: how to decide its appropriateness. World J Methodol 11:116\u2013129","journal-title":"World J Methodol"},{"key":"7537_CR42","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1093\/ndt\/gfs279","volume":"27","author":"T Barbour","year":"2012","unstructured":"Barbour T, Johnson S, Cohney S, Hughes P (2012) Thrombotic microangiopathy and associated renal disorders. Nephrol Dial Transplant 27:2673\u20132685","journal-title":"Nephrol Dial Transplant"},{"key":"7537_CR43","doi-asserted-by":"publisher","first-page":"300","DOI":"10.2215\/CJN.00620117","volume":"13","author":"V Brocklebank","year":"2018","unstructured":"Brocklebank V, Wood KM, Kavanagh D (2018) Thrombotic Microangiopathy and the Kidney. Clin J Am Soc Nephrol 13:300\u2013317","journal-title":"Clin J Am Soc Nephrol"},{"key":"7537_CR44","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","volume":"390","author":"F Fakhouri","year":"2017","unstructured":"Fakhouri F, Zuber J, Fremeaux-Bacchi V, Loirat C (2017) Haemolytic uraemic syndrome. Lancet (London, England) 390:681\u2013696","journal-title":"Lancet (London, England)"},{"key":"7537_CR45","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jpeds.2007.03.055","volume":"151","author":"AM Waters","year":"2007","unstructured":"Waters AM, Kerecuk L, Luk D, Haq MR, Fitzpatrick MM, Gilbert RD, Inward C, Jones C, Pichon B, Reid C, Slack MP, Van\u2019t Hoff W, Dillon MJ, Taylor CM, Tullus K (2007) Hemolytic uremic syndrome associated with invasive pneumococcal disease: the United kingdom experience. J Pediatr 151:140\u2013144","journal-title":"J Pediatr"},{"key":"7537_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0295011","volume":"18","author":"M Walle","year":"2023","unstructured":"Walle M, Arkew M, Asmerom H, Tesfaye A, Getu F (2023) The diagnostic accuracy of mean platelet volume in differentiating immune thrombocytopenic purpura from hypo-productive thrombocytopenia: a systematic review and meta-analysis. PLoS ONE 18:e0295011","journal-title":"PLoS ONE"},{"key":"7537_CR47","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.1007\/s00467-021-05108-6","volume":"36","author":"S Loos","year":"2021","unstructured":"Loos S, Oh J, van de Loo L, Kemper MJ, Blohm M, Schild R (2021) Hemoconcentration and predictors in Shiga toxin-producing E. coli-hemolytic uremic syndrome (STEC-HUS). Pediatr Nephrol 36:3777\u20133783","journal-title":"Pediatr Nephrol"},{"key":"7537_CR48","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/35097008","volume":"413","author":"GG Levy","year":"2001","unstructured":"Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, Sarode R, Shurin SB, Chandrasekaran V, Stabler SP, Sabio H, Bouhassira EE, Upshaw JD Jr, Ginsburg D, Tsai HM (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413:488\u2013494","journal-title":"Nature"},{"key":"7537_CR49","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1007\/s00467-007-0518-y","volume":"23","author":"L Copelovitch","year":"2008","unstructured":"Copelovitch L, Kaplan BS (2008) Streptococcus pneumoniae-associated hemolytic uremic syndrome. Pediatr Nephrol 23:1951\u20131956","journal-title":"Pediatr Nephrol"},{"key":"7537_CR50","doi-asserted-by":"crossref","unstructured":"Iba T, Watanabe E, Umemura Y, Wada T, Hayashida K, Kushimoto S, Japanese Surviving Sepsis Campaign Guideline Working Group for disseminated intravascular c, Wada H (2019) Sepsis-associated disseminated intravascular coagulation and its differential diagnoses. J Intensive Care 7:32","DOI":"10.1186\/s40560-019-0387-z"},{"key":"7537_CR51","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s004670100564","volume":"16","author":"S Nathanson","year":"2001","unstructured":"Nathanson S, Deschenes G (2001) Prognosis of Streptococcus pneumoniae-induced hemolytic uremic syndrome. Pediatr Nephrol 16:362\u2013365","journal-title":"Pediatr Nephrol"},{"key":"7537_CR52","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1182\/blood.2019000936","volume":"135","author":"SW Canna","year":"2020","unstructured":"Canna SW, Marsh RA (2020) Pediatric hemophagocytic lymphohistiocytosis. Blood 135:1332\u20131343","journal-title":"Blood"},{"key":"7537_CR53","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1007\/s00467-022-05775-z","volume":"38","author":"BR Stotter","year":"2023","unstructured":"Stotter BR, Cody E, Gu H, Daga A, Greenbaum LA, Duong MD, Mazo A, Goilav B, Boneparth A, Kallash M, Zeid A, Seeherunvong W, Scobell RR, Alhamoud I, Carter CE, Shah S, Straatmann CE, Dixon BP, Cooper JC, Nelson RD, Levy DM, Brunner HI, Verghese PS, Wenderfer SE (2023) Acute kidney injury requiring kidney replacement therapy in childhood lupus nephritis: a cohort study of the Pediatric Nephrology Research Consortium and Childhood Arthritis and Rheumatology Research Alliance. Pediatr Nephrol 38:1653\u20131665","journal-title":"Pediatr Nephrol"},{"key":"7537_CR54","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1093\/rheumatology\/keq311","volume":"50","author":"MH Chen","year":"2011","unstructured":"Chen MH, Chen MH, Chen WS, Mu-Hsin Chang P, Lee HT, Lin HY, Huang DF (2011) Thrombotic microangiopathy in systemic lupus erythematosus: a cohort study in North Taiwan. Rheumatology (Oxford) 50:768\u2013775","journal-title":"Rheumatology (Oxford)"},{"key":"7537_CR55","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1182\/bloodadvances.2018019596","volume":"2","author":"MH Park","year":"2018","unstructured":"Park MH, Caselman N, Ulmer S, Weitz IC (2018) Complement-mediated thrombotic microangiopathy associated with lupus nephritis. Blood Adv 2:2090\u20132094","journal-title":"Blood Adv"},{"key":"7537_CR56","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1053\/j.ajkd.2015.02.340","volume":"66","author":"H Izzedine","year":"2015","unstructured":"Izzedine H, Perazella MA (2015) Thrombotic microangiopathy, cancer, and cancer drugs. Am J Kidney Dis 66:857\u2013868","journal-title":"Am J Kidney Dis"},{"key":"7537_CR57","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/978-3-030-20315-3_10","volume":"179","author":"MR Thomas","year":"2019","unstructured":"Thomas MR, Scully M (2019) Microangiopathy in cancer: causes, consequences, and management. Cancer Treat Res 179:151\u2013158","journal-title":"Cancer Treat Res"},{"key":"7537_CR58","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1016\/j.ekir.2021.03.885","volume":"6","author":"G Ardissino","year":"2021","unstructured":"Ardissino G, Longhi S, Porcaro L, Pintarelli G, Strumbo B, Capone V, Cresseri D, Loffredo G, Tel F, Salardi S, Sgarbanti M, Martelli L, Rodrigues EM, Borsa-Ghiringhelli N, Montini G, Seia M, Cugno M, Carfagna F, Consonni D, Tedeschi S (2021) Risk of atypical HUS among family members of patients carrying complement regulatory gene abnormality. Kidney Int Rep 6:1614\u20131621","journal-title":"Kidney Int Rep"},{"key":"7537_CR59","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/ng.2590","volume":"45","author":"M Lemaire","year":"2013","unstructured":"Lemaire M, Fremeaux-Bacchi V, Schaefer F, Choi M, Tang WH, Le Quintrec M, Fakhouri F, Taque S, Nobili F, Martinez F, Ji W, Overton JD, Mane SM, Nurnberg G, Altmuller J, Thiele H, Morin D, Deschenes G, Baudouin V, Lifton RP (2013) Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet 45:531\u2013536","journal-title":"Nat Genet"},{"issue":"14","key":"7537_CR60","doi-asserted-by":"publisher","first-page":"7604","DOI":"10.3390\/ijms25147604","volume":"25","author":"KL Wijnsma","year":"2024","unstructured":"Wijnsma KL, Schijvens AM, Bouwmeester RN, Aarts LAM, van den Heuvel LBP, Haaxma CA, van de Kar N (2024) Mutations in genes encoding subunits of the RNA exosome as a potential novel cause of thrombotic microangiopathy. Int J Mol Sci 25(14):7604. https:\/\/doi.org\/10.3390\/ijms25147604","journal-title":"Int J Mol Sci"},{"key":"7537_CR61","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00467-016-3399-0","volume":"32","author":"BB Beck","year":"2017","unstructured":"Beck BB, van Spronsen F, Diepstra A, Berger RM, Komhoff M (2017) Renal thrombotic microangiopathy in patients with cblC defect: review of an under-recognized entity. Pediatr Nephrol 32:733\u2013741","journal-title":"Pediatr Nephrol"},{"key":"7537_CR62","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00467-016-3399-0","volume":"32","author":"BB Beck","year":"2017","unstructured":"Beck BB, van Spronsen F, Diepstra A, Berger RM, K\u00f6mhoff M (2017) Renal thrombotic microangiopathy in patients with cblC defect: review of an under-recognized entity. Pediatr Nephrol 32:733\u2013741","journal-title":"Pediatr Nephrol"},{"key":"7537_CR63","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1007\/s00467-024-06355-z","volume":"39","author":"A Rosales","year":"2024","unstructured":"Rosales A, Kuppelwieser S, Giner T, Hofer J, Riedl Khursigara M, Orth-Holler D, Borena W, Cortina G, Jungraithmayr T, Wurzner R, German-Austrian HUSSG (2024) Outcome 10 years after Shiga toxin-producing E. coli (STEC)-associated hemolytic uremic syndrome: importance of long-term follow-up. Pediatr Nephrol 39:2459\u20132465","journal-title":"Pediatr Nephrol"},{"key":"7537_CR64","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1002\/pbc.24612","volume":"60","author":"JA Reese","year":"2013","unstructured":"Reese JA, Muthurajah DS, Kremer Hovinga JA, Vesely SK, Terrell DR, George JN (2013) Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features. Pediatr Blood Cancer 60:1676\u20131682","journal-title":"Pediatr Blood Cancer"},{"key":"7537_CR65","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/nrneph.2012.195","volume":"8","author":"M Noris","year":"2012","unstructured":"Noris M, Mescia F, Remuzzi G (2012) STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 8:622\u2013633","journal-title":"Nat Rev Nephrol"},{"key":"7537_CR66","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1182\/asheducation.V2012.1.604.3798564","volume":"2012","author":"JN George","year":"2012","unstructured":"George JN, Al-Nouri ZL (2012) Diagnostic and therapeutic challenges in the thrombotic thrombocytopenic purpura and hemolytic uremic syndromes. Hematology Am Soc Hematol Educ Program 2012:604\u2013609","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"7537_CR67","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1007\/s00467-019-04342-3","volume":"35","author":"RR Scobell","year":"2020","unstructured":"Scobell RR, Kaplan BS, Copelovitch L (2020) New insights into the pathogenesis of Streptococcus pneumoniae-associated hemolytic uremic syndrome. Pediatr Nephrol 35:1585\u20131591","journal-title":"Pediatr Nephrol"},{"key":"7537_CR68","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1097\/01.inf.0000223494.83542.ad","volume":"25","author":"DT Huang","year":"2006","unstructured":"Huang DT, Chi H, Lee HC, Chiu NC, Huang FY (2006) T-antigen activation for prediction of pneumococcus-induced hemolytic uremic syndrome and hemolytic anemia. Pediatr Infect Dis J 25:608\u2013610","journal-title":"Pediatr Infect Dis J"},{"key":"7537_CR69","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1007\/s00467-012-2383-6","volume":"28","author":"JM Spinale","year":"2013","unstructured":"Spinale JM, Ruebner RL, Copelovitch L, Kaplan BS (2013) Long-term outcomes of Shiga toxin hemolytic uremic syndrome. Pediatr Nephrol 28:2097\u20132105","journal-title":"Pediatr Nephrol"},{"key":"7537_CR70","doi-asserted-by":"crossref","unstructured":"Freedman SB, Xie J, Nettel-Aguirre A, Lee B, Chui L, Pang XL, Zhuo R, Parsons B, Dickinson JA, Vanderkooi OG, Ali S, Osterreicher L, Lowerison K, Tarr PI, Alberta Provincial Pediatric EnTeric Infection T (2017) Enteropathogen detection in children with diarrhoea, or vomiting, or both, comparing rectal flocked swabs with stool specimens: an outpatient cohort study. Lancet Gastroenterol Hepatol 2:662\u2013669","DOI":"10.1093\/ofid\/ofx162.081"},{"key":"7537_CR71","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMra2108739","volume":"389","author":"SB Freedman","year":"2023","unstructured":"Freedman SB, van de Kar N, Tarr PI (2023) Shiga toxin-producing Escherichia coli and the hemolytic-uremic syndrome. N Engl J Med 389:1402\u20131414","journal-title":"N Engl J Med"},{"key":"7537_CR72","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s10096-019-03738-1","volume":"39","author":"LF Alconcher","year":"2020","unstructured":"Alconcher LF, Rivas M, Lucarelli LI, Galavotti J, Rizzo M (2020) Shiga toxin-producing Escherichia coli in household members of children with hemolytic uremic syndrome. Eur J Clin Microbiol Infect Dis 39:427\u2013432","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"7537_CR73","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s00467-022-05671-6","volume":"38","author":"GA Fiorentino","year":"2023","unstructured":"Fiorentino GA, Miliwebsky E, Ramos MV, Zolezzi G, Chinen I, Guzman G, Nocera R, Fernandez-Brando R, Santiago A, Exeni R, Palermo MS (2023) Etiological diagnosis of post-diarrheal hemolytic uremic syndrome (HUS): humoral response contribution. Pediatr Nephrol 38:739\u2013748","journal-title":"Pediatr Nephrol"},{"key":"7537_CR74","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.01003-24","volume":"62","author":"SM Landivar","year":"2024","unstructured":"Landivar SM, Melli LJ, Maiztegui C, Schesi C, Baschkier A, Francisetti V, Chinen I, Miliwebsky E, Rivas M, Comerci DJ, Ugalde JE, Ciocchini AE (2024) A novel multiplex and glycoprotein-based immunochromatographic serologic IgM test for the rapid diagnosis of Escherichia coli O157 and O145 causing bloody diarrhea and hemolytic uremic syndrome. J Clin Microbiol 62:e0100324","journal-title":"J Clin Microbiol"},{"key":"7537_CR75","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","volume":"124","author":"M Noris","year":"2014","unstructured":"Noris M, Galbusera M, Gastoldi S, Macor P, Banterla F, Bresin E, Tripodo C, Bettoni S, Donadelli R, Valoti E, Tedesco F, Amore A, Coppo R, Ruggenenti P, Gotti E, Remuzzi G (2014) Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood 124:1715\u20131726","journal-title":"Blood"},{"key":"7537_CR76","doi-asserted-by":"publisher","first-page":"1112257","DOI":"10.3389\/fimmu.2023.1112257","volume":"14","author":"S Gastoldi","year":"2023","unstructured":"Gastoldi S, Aiello S, Galbusera M, Breno M, Alberti M, Bresin E, Mele C, Piras R, Liguori L, Santarsiero D, Benigni A, Remuzzi G, Noris M (2023) An ex vivo test to investigate genetic factors conferring susceptibility to atypical haemolytic uremic syndrome. Front Immunol 14:1112257","journal-title":"Front Immunol"},{"key":"7537_CR77","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/cge.14105","volume":"101","author":"N Canpolat","year":"2022","unstructured":"Canpolat N, Liu D, Atayar E, Saygili S, Kara NS, Westfall TA, Ding Q, Brown BJ, Braun TA, Slusarski D, Karli Oguz K, Ozluk Y, Tuysuz B, Tastemel Ozturk T, Sever L, Sezerman OU, Topaloglu R, Caliskan S, Attanasio M, Ozaltin F (2022) A splice site mutation in the TSEN2 causes a new syndrome with craniofacial and central nervous system malformations, and atypical hemolytic uremic syndrome. Clin Genet 101:346\u2013358","journal-title":"Clin Genet"},{"key":"7537_CR78","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1007\/s00467-022-05566-6","volume":"37","author":"C Van Quekelberghe","year":"2022","unstructured":"Van Quekelberghe C, Latta K, Kunzmann S, Grohmann M, Hansen M (2022) Atypical hemolytic uremic syndrome induced by SARS-CoV2 infection in infants with EXOSC3 mutation. Pediatr Nephrol 37:2781\u20132784","journal-title":"Pediatr Nephrol"},{"key":"7537_CR79","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12882-017-0643-1","volume":"18","author":"JL Alge","year":"2017","unstructured":"Alge JL, Wenderfer SE, Hicks J, Bekheirnia MR, Schady DA, Kain JS, Braun MC (2017) Hemolytic uremic syndrome as the presenting manifestation of WT1 mutation and Denys-Drash syndrome: a case report. BMC Nephrol 18:243","journal-title":"BMC Nephrol"},{"key":"7537_CR80","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1681\/ASN.2015101189","volume":"28","author":"RC Challis","year":"2017","unstructured":"Challis RC, Ring T, Xu Y, Wong EK, Flossmann O, Roberts IS, Ahmed S, Wetherall M, Salkus G, Brocklebank V, Fester J, Strain L, Wilson V, Wood KM, Marchbank KJ, Santibanez-Koref M, Goodship TH, Kavanagh D (2017) Thrombotic microangiopathy in inverted formin 2-mediated renal disease. J Am Soc Nephrol 28:1084\u20131091","journal-title":"J Am Soc Nephrol"},{"key":"7537_CR81","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1016\/j.ekir.2023.07.024","volume":"8","author":"ZR Song","year":"2023","unstructured":"Song ZR, Jiang L, Li Y, Xiang CG, Liu ZY, Li MS, Zhang H, Zhou XJ (2023) Kidney-predominant thrombotic microangiopathy associated with TREX1 frameshift mutation. Kidney Int Rep 8:2172\u20132176","journal-title":"Kidney Int Rep"},{"key":"7537_CR82","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Loirat C (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368:2169\u20132181","journal-title":"N Engl J Med"},{"key":"7537_CR83","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1053\/j.ajkd.2014.01.434","volume":"64","author":"G Ardissino","year":"2014","unstructured":"Ardissino G, Testa S, Possenti I, Tel F, Paglialonga F, Salardi S, Tedeschi S, Belingheri M, Cugno M (2014) Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. Am J Kidney Dis 64:633\u2013637","journal-title":"Am J Kidney Dis"},{"key":"7537_CR84","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1182\/blood.2020009280","volume":"137","author":"F Fakhouri","year":"2021","unstructured":"Fakhouri F, Fila M, Hummel A, Ribes D, Sellier-Leclerc AL, Ville S, Pouteil-Noble C, Coindre JP, Le Quintrec M, Rondeau E, Boyer O, Provot F, Djeddi D, Hanf W, Delmas Y, Louillet F, Lahoche A, Favre G, Chatelet V, Fremeaux-Bacchi V (2021) Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study. Blood 137:2438\u20132449","journal-title":"Blood"},{"key":"7537_CR85","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ekir.2022.10.013","volume":"8","author":"RN Bouwmeester","year":"2023","unstructured":"Bouwmeester RN, Duineveld C, Wijnsma KL, Bemelman FJ, van der Heijden JW, van Wijk JAE, Bouts AHM, van de Wetering J, Dorresteijn E, Berger SP, Gracchi V, van Zuilen AD, Keijzer-Veen MG, de Vries APJ, van Rooij RWG, Engels F, Altena W, de Wildt R, van Kempen E, van de Kar N (2023) Early Eculizumab withdrawal in patients with atypical hemolytic uremic syndrome in native kidneys is safe and cost-effective: results of the CUREiHUS study. Kidney Int Rep 8:91\u2013102","journal-title":"Kidney Int Rep"},{"key":"7537_CR86","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1681\/ASN.2012090884","volume":"24","author":"E Bresin","year":"2013","unstructured":"Bresin E, Rurali E, Caprioli J, Sanchez-Corral P, Fremeaux-Bacchi V, Rodriguez De Cordoba S, Pinto S, Goodship THJ, Alberti M, Ribes D, Valoti E, Remuzzi G, Noris M (2013) Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol 24:475\u2013486","journal-title":"J Am Soc Nephrol"},{"key":"7537_CR87","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1053\/j.ajkd.2017.06.024","volume":"70","author":"C Duineveld","year":"2017","unstructured":"Duineveld C, Verhave JC, Berger SP, van de Kar N, Wetzels JFM (2017) Living donor kidney transplantation in atypical hemolytic uremic syndrome: a case series. Am J Kidney Dis 70:770\u2013777","journal-title":"Am J Kidney Dis"},{"key":"7537_CR88","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/ajt.12077","volume":"13","author":"M Le Quintrec","year":"2013","unstructured":"Le Quintrec M, Zuber J, Moulin B, Kamar N, Jablonski M, Lionet A, Chatelet V, Mousson C, Mourad G, Bridoux F, Cassuto E, Loirat C, Rondeau E, Delahousse M, Fr\u00e9meaux-Bacchi V (2013) Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant 13:663\u2013675","journal-title":"Am J Transplant"},{"key":"7537_CR89","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.ekir.2018.11.010","volume":"4","author":"AM Siedlecki","year":"2019","unstructured":"Siedlecki AM, Isbel N, Vande Walle J, James Eggleston J, Cohen DJ (2019) Eculizumab use for kidney transplantation in patients with a diagnosis of atypical hemolytic uremic syndrome. Kidney Int Rep 4:434\u2013446","journal-title":"Kidney Int Rep"},{"key":"7537_CR90","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41581-021-00424-4","volume":"17","author":"F Fakhouri","year":"2021","unstructured":"Fakhouri F, Fremeaux-Bacchi V (2021) Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics. Nat Rev Nephrol 17:543\u2013553","journal-title":"Nat Rev Nephrol"},{"key":"7537_CR91","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1073\/pnas.0603420103","volume":"104","author":"E Goicoechea de Jorge","year":"2007","unstructured":"Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J, Carreras L, Arranz EA, Garrido CA, Lopez-Trascasa M, Sanchez-Corral P, Morgan BP, Rodriguez de Cordoba S (2007) Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A 104:240\u2013245","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7537_CR92","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1681\/ASN.2019050515","volume":"31","author":"PF Zipfel","year":"2020","unstructured":"Zipfel PF, Wiech T, Stea ED, Skerka C (2020) CFHR gene variations provide insights in the pathogenesis of the kidney diseases atypical hemolytic uremic syndrome and C3 glomerulopathy. J Am Soc Nephrol 31:241\u2013256","journal-title":"J Am Soc Nephrol"},{"key":"7537_CR93","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1182\/blood-2009-05-221549","volume":"115","author":"I Moore","year":"2010","unstructured":"Moore I, Strain L, Pappworth I, Kavanagh D, Barlow PN, Herbert AP, Schmidt CQ, Staniforth SJ, Holmes LV, Ward R, Morgan L, Goodship TH, Marchbank KJ (2010) Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 115:379\u2013387","journal-title":"Blood"},{"key":"7537_CR94","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.imbio.2016.05.002","volume":"221","author":"PJ Gleeson","year":"2016","unstructured":"Gleeson PJ, Wilson V, Cox TE, Sharma SD, Smith-Jackson K, Strain L, Lappin D, McHale T, Kavanagh D, Goodship TH (2016) Chromosomal rearrangement-A rare cause of complement factor I associated atypical haemolytic uraemic syndrome. Immunobiology 221:1124\u20131130","journal-title":"Immunobiology"},{"key":"7537_CR95","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/ajmg.10499","volume":"111","author":"JL Van Hove","year":"2002","unstructured":"Van Hove JL, Van Damme-Lombaerts R, Grunewald S, Peters H, Van Damme B, Fryns JP, Arnout J, Wevers R, Baumgartner ER, Fowler B (2002) Cobalamin disorder Cbl-C presenting with late-onset thrombotic microangiopathy. American J Med Genet 111:195\u2013201","journal-title":"American J Med Genet"},{"key":"7537_CR96","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL, Committee ALQA (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17:405\u2013424","journal-title":"Genet Med"},{"key":"7537_CR97","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/ki.2011.330","volume":"81","author":"D Kavanagh","year":"2012","unstructured":"Kavanagh D, Anderson HE (2012) Interpretation of genetic variants of uncertain significance in atypical hemolytic uremic syndrome. Kidney Int 81:11\u201313","journal-title":"Kidney Int"},{"key":"7537_CR98","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1182\/blood.2020006931","volume":"136","author":"E Arjona","year":"2020","unstructured":"Arjona E, Huerta A, Goicoechea de Jorge E, Rodriguez de Cordoba S (2020) Familial risk of developing atypical hemolytic-uremic syndrome. Blood 136:1558\u20131561","journal-title":"Blood"},{"key":"7537_CR99","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1093\/hmg\/ddac060","volume":"31","author":"N Tzoumas","year":"2022","unstructured":"Tzoumas N, Kavanagh D, Cordell HJ, Lotery AJ, Patel PJ, Steel DH (2022) Rare complement factor I variants associated with reduced macular thickness and age-related macular degeneration in the UK Biobank. Hum Mol Genet 31:2678\u20132692","journal-title":"Hum Mol Genet"},{"key":"7537_CR100","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","volume":"91","author":"TH Goodship","year":"2017","unstructured":"Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Fremeaux-Bacchi V, Kavanagh D, Nester CM, Noris M, Pickering MC, Rodriguez de Cordoba S, Roumenina LT, Sethi S, Smith RJ, Conference P (2017) Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference. Kidney Int 91:539\u2013551","journal-title":"Kidney Int"},{"key":"7537_CR101","doi-asserted-by":"crossref","unstructured":"Greenbaum LA, Dixon BP, Kavanagh D, Kang HG, Chen J, Garlo K, Ogawa M, Cataland S, Luque Y, Taylor V, Miyakawa Y (2025) Ravulizumab in atypical hemolytic uremic syndrome: time-to-treatment analysis from a phase 3 trial. J Am Soc Nephrol 36(10S):SA-OR049","DOI":"10.1681\/ASN.2025rfm1nz62"},{"key":"7537_CR102","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S0161-5890(96)00078-8","volume":"33","author":"TC Thomas","year":"1996","unstructured":"Thomas TC, Rollins SA, Rother RP, Giannoni MA, Hartman SL, Elliott EA, Nye SH, Matis LA, Squinto SP, Evans MJ (1996) Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol 33:1389\u20131401","journal-title":"Mol Immunol"},{"key":"7537_CR103","doi-asserted-by":"crossref","unstructured":"Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon SS, Kavanagh D, Haller H, Study G (2020) The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment. Kidney Int 97:1287\u20131296","DOI":"10.1016\/j.kint.2020.11.001"},{"key":"7537_CR104","doi-asserted-by":"publisher","first-page":"261","DOI":"10.5414\/CN110516","volume":"97","author":"I Tomazos","year":"2022","unstructured":"Tomazos I, Hatswell AJ, Cataland S, Chen P, Freemantle N, Lommele A, Deighton K, Knowles E, Sheerin NS, Rondeau E (2022) Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: an indirect comparison using clinical trial data. Clin Nephrol 97:261\u2013272","journal-title":"Clin Nephrol"},{"key":"7537_CR105","doi-asserted-by":"crossref","unstructured":"Barbour T, Scully M, Ariceta G, Cataland S, Garlo K, Heyne N, Luque Y, Menne J, Miyakawa Y, Yoon SS, Kavanagh D, Study Group M (2021) Long-term efficacy and safety of the long-acting complement C5 Inhibitor Ravulizumab for the treatment of atypical hemolytic uremic syndrome in adults. Kidney Int Rep 6:1603\u20131613","DOI":"10.1093\/ndt\/gfaa139.SO054"},{"key":"7537_CR106","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-024-03638-3","volume":"25","author":"K Schonfelder","year":"2024","unstructured":"Schonfelder K, Kuhne L, Schulte-Kemna L, Kaufeld J, Rohn H, Kribben A, Schroppel B, Brinkkotter PT, Gackler A (2024) Clinical efficacy and safety of switching from eculizumab to ravulizumab in adult patients with aHUS- real-world data. BMC Nephrol 25:202","journal-title":"BMC Nephrol"},{"key":"7537_CR107","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1182\/blood-2019-122421","volume":"134","author":"S Cataland","year":"2019","unstructured":"Cataland S, Ariceta G, Chen P, Dixon BP, Garlo K, Greenbaum LA, Rondeau E, Scully M, Ortiz S (2019) Discordance between free C5 and CH50 complement assays in measuring complement C5 inhibition in patients with aHUS treated with ravulizumab. Blood 134:1099","journal-title":"Blood"},{"key":"7537_CR108","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000001020","author":"A Java","year":"2026","unstructured":"Java A, Subramanian A, Nester C (2026) Practical considerations for infection prevention with the clinical use of complement inhibitors. Clin J Am Soc Nephrol. https:\/\/doi.org\/10.2215\/CJN.0000001020","journal-title":"Clin J Am Soc Nephrol"},{"key":"7537_CR109","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00467-014-2990-5","volume":"30","author":"W Hayes","year":"2015","unstructured":"Hayes W, Tschumi S, Ling SC, Feber J, Kirschfink M, Licht C (2015) Eculizumab hepatotoxicity in pediatric aHUS. Pediatr Nephrol 30:775\u2013781","journal-title":"Pediatr Nephrol"},{"key":"7537_CR110","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1055\/s-0034-1376154","volume":"40","author":"J Hofer","year":"2014","unstructured":"Hofer J, Giner T, Safouh H (2014) Diagnosis and treatment of the hemolytic uremic syndrome disease spectrum in developing regions. Semin Thromb Hemost 40:478\u2013486","journal-title":"Semin Thromb Hemost"},{"key":"7537_CR111","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00467-008-0964-1","volume":"24","author":"G Ariceta","year":"2009","unstructured":"Ariceta G, Besbas N, Johnson S, Karpman D, Landau D, Licht C, Loirat C, Pecoraro C, Taylor CM, Van de Kar N, Vandewalle J, Zimmerhackl LB (2009) Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 24:687\u2013696","journal-title":"Pediatr Nephrol"},{"key":"7537_CR112","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/jca.22043","volume":"38","author":"L Connelly-Smith","year":"2023","unstructured":"Connelly-Smith L, Alquist CR, Aqui NA, Hofmann JC, Klingel R, Onwuemene OA, Patriquin CJ, Pham HP, Sanchez AP, Schneiderman J, Witt V, Zantek ND, Dunbar NM (2023) Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American Society for Apheresis: the ninth special issue. J Clin Apher 38:77\u2013278","journal-title":"J Clin Apher"},{"key":"7537_CR113","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/jca.21705","volume":"34","author":"A Padmanabhan","year":"2019","unstructured":"Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, Pham HP, Schneiderman J, Witt V, Wu Y, Zantek ND, Dunbar NM, Schwartz GEJ (2019) Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American Society for Apheresis: the eighth special issue. J Clin Apher 34:171\u2013354","journal-title":"J Clin Apher"},{"key":"7537_CR114","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1007\/s00467-024-06279-8","volume":"39","author":"S Thangaraju","year":"2024","unstructured":"Thangaraju S, Khandelwal P, Mishra K, Kumar M, Puraswani M, Saini R, Hari P, Coshic P, Sinha A, Bagga A (2024) Abbreviated protocol of plasma exchanges for patients with anti-factor H associated hemolytic uremic syndrome. Pediatr Nephrol 39:2091\u20132097","journal-title":"Pediatr Nephrol"},{"key":"7537_CR115","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1007\/s00467-008-0833-y","volume":"23","author":"JC Davin","year":"2008","unstructured":"Davin JC, Strain L, Goodship TH (2008) Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation. Pediatr Nephrol 23:1517\u20131521","journal-title":"Pediatr Nephrol"},{"key":"7537_CR116","doi-asserted-by":"crossref","unstructured":"Ariceta G, Besbas N, Johnson S, Karpman D, Landau D, Licht C, Loirat C, Pecoraro C, Taylor CM, Van de Kar N, Vandewalle J, Zimmerhackl LB, European Paediatric Study Group for HUS (2009) Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 24:687-696","DOI":"10.1007\/s00467-008-0964-1"},{"key":"7537_CR117","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-054536","volume":"12","author":"S Dunn","year":"2022","unstructured":"Dunn S, Brocklebank V, Bryant A, Carnell S, Chadwick TJ, Johnson S, Kavanagh D, Lecouturier J, Malina M, Moloney E, Oluboyede Y, Weetman C, Wong EKS, Woodward L, Sheerin N (2022) Safety and impact of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome: protocol for a multicentre, open-label, prospective, single-arm study. BMJ Open 12:e054536","journal-title":"BMJ Open"},{"key":"7537_CR118","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1159\/000513009","volume":"145","author":"D Wu","year":"2021","unstructured":"Wu D, Chen J, Ling C, Chen Z, Fan J, Sun Q, Meng Q, Liu X (2021) Clinical and genetic characteristics of atypical hemolytic uremic syndrome in children: a Chinese cohort study. Nephron 145:415\u2013427","journal-title":"Nephron"},{"key":"7537_CR119","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.kint.2017.04.028","volume":"92","author":"V Brocklebank","year":"2017","unstructured":"Brocklebank V, Johnson S, Sheerin TP, Marks SD, Gilbert RD, Tyerman K, Kinoshita M, Awan A, Kaur A, Webb N, Hegde S, Finlay E, Fitzpatrick M, Walsh PR, Wong EKS, Booth C, Kerecuk L, Salama AD, Almond M, Inward C, Goodship TH, Sheerin NS, Marchbank KJ, Kavanagh D (2017) Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland. Kidney Int 92:1261\u20131271","journal-title":"Kidney Int"},{"key":"7537_CR120","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1093\/ndt\/gfx196","volume":"33","author":"KL Wijnsma","year":"2018","unstructured":"Wijnsma KL, Duineveld C, Volokhina EB, van den Heuvel LP, van de Kar N, Wetzels JFM (2018) Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome. Nephrol Dial Transplant 33:635\u2013645","journal-title":"Nephrol Dial Transplant"},{"key":"7537_CR121","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2215\/CJN.06440616","volume":"12","author":"F Fakhouri","year":"2017","unstructured":"Fakhouri F, Fila M, Provot F, Delmas Y, Barbet C, Chatelet V, Rafat C, Cailliez M, Hogan J, Servais A, Karras A, Makdassi R, Louillet F, Coindre JP, Rondeau E, Loirat C, Fremeaux-Bacchi V (2017) Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation. Clin J Am Soc Nephrol 12:50\u201359","journal-title":"Clin J Am Soc Nephrol"},{"key":"7537_CR122","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1007\/s40620-021-01212-w","volume":"35","author":"E Baskin","year":"2022","unstructured":"Baskin E, Fidan K, Gulhan B, Gulleroglu K, Canpolat N, Yilmaz A, Parmakiz G, Ozcakar ZB, Ozaltin F, Soylemezoglu O (2022) Eculizumab treatment and discontinuation in pediatric patients with atypical hemolytic uremic syndrome: a multicentric retrospective study. J Nephrol 35:1213\u20131222","journal-title":"J Nephrol"},{"key":"7537_CR123","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1182\/bloodadvances.2021006416","volume":"7","author":"AA Acosta-Medina","year":"2023","unstructured":"Acosta-Medina AA, Moyer AM, Go RS, Willrich MAV, Fervenza FC, Leung N, Bourlon C, Winters JL, Spears GM, Bryant SC, Sridharan M (2023) Complement gene variant effect on relapse of complement-mediated thrombotic microangiopathy after eculizumab cessation. Blood Adv 7:340\u2013350","journal-title":"Blood Adv"},{"key":"7537_CR124","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.kint.2024.09.012","volume":"106","author":"D Kavanagh","year":"2024","unstructured":"Kavanagh D, Ardissino G, Brocklebank V, Bouwmeester RN, Bagga A, Ter Heine R, Johnson S, Licht C, Ma ALT, Noris M, Praga M, Rondeau E, Sinha A, Smith RJH, Sheerin NS, Trimarchi H, Wetzels JFM, Vivarelli M, Van de Kar N, Forum P (2024) Outcomes from the international society of nephrology hemolytic uremic syndromes international forum. Kidney Int 106:1038\u20131050","journal-title":"Kidney Int"},{"key":"7537_CR125","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1182\/blood-2014-06-579953","volume":"125","author":"S Bruneau","year":"2015","unstructured":"Bruneau S, Neel M, Roumenina LT, Frimat M, Laurent L, Fremeaux-Bacchi V, Fakhouri F (2015) Loss of DGKepsilon induces endothelial cell activation and death independently of complement activation. Blood 125:1038\u20131046","journal-title":"Blood"},{"issue":"9","key":"7537_CR126","doi-asserted-by":"publisher","first-page":"e146959","DOI":"10.1172\/jci.insight.146959","volume":"6","author":"D Liu","year":"2021","unstructured":"Liu D, Ding Q, Dai DF, Padhy B, Nayak MK, Li C, Purvis M, Jin H, Shu C, Chauhan AK, Huang CL, Attanasio M (2021) Loss of diacylglycerol kinase epsilon causes thrombotic microangiopathy by impairing endothelial VEGFA signaling. JCI Insight 6(9):e146959. https:\/\/doi.org\/10.1172\/jci.insight.146959","journal-title":"JCI Insight"},{"key":"7537_CR127","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12882-021-02352-8","volume":"22","author":"M Alabdulqader","year":"2021","unstructured":"Alabdulqader M, Alfakeeh K (2021) A patient with a homozygous diacylglycerol kinase epsilon (DGKE) gene mutation with atypical haemolytic uraemic syndrome and low C3 responded well to eculizumab: a case report. BMC Nephrol 22:140","journal-title":"BMC Nephrol"},{"key":"7537_CR128","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.2215\/CJN.01640214","volume":"9","author":"D Sanchez Chinchilla","year":"2014","unstructured":"Sanchez Chinchilla D, Pinto S, Hoppe B, Adragna M, Lopez L, Justa Roldan ML, Pena A, Lopez Trascasa M, Sanchez-Corral P, Rodriguez de Cordoba S (2014) Complement mutations in diacylglycerol kinase-epsilon-associated atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 9:1611\u20131619","journal-title":"Clin J Am Soc Nephrol"},{"key":"7537_CR129","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/ped.12953","volume":"58","author":"A Adrovic","year":"2016","unstructured":"Adrovic A, Canpolat N, Caliskan S, Sever L, Kiykim E, Agbas A, Baumgartner MR (2016) Cobalamin C defect-hemolytic uremic syndrome caused by new mutation in <italic>MMACHC<\/italic>. Pediatr Int 58:763\u2013765","journal-title":"Pediatr Int"},{"key":"7537_CR130","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1007\/s004310051190","volume":"158","author":"P Labrune","year":"1999","unstructured":"Labrune P, Zittoun J, Duvaltier I, Trioche P, Marquet J, Niaudet P, Odievre M (1999) Haemolytic uraemic syndrome and pulmonary hypertension in a patient with methionine synthase deficiency. Eur J Pediatr 158:734\u2013739","journal-title":"Eur J Pediatr"},{"key":"7537_CR131","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa0810739","volume":"361","author":"M Delvaeye","year":"2009","unstructured":"Delvaeye M, Noris M, De Vriese A, Esmon CT, Esmon NL, Ferrell G, Del-Favero J, Plaisance S, Claes B, Lambrechts D, Zoja C, Remuzzi G, Conway EM (2009) Thrombomodulin mutations in atypical hemolytic-uremic syndrome. New Engl J Med 361:345\u2013357","journal-title":"New Engl J Med"},{"key":"7537_CR132","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.4049\/jimmunol.1701695","volume":"200","author":"AJ Osborne","year":"2018","unstructured":"Osborne AJ, Breno M, Borsa NG, Bu F, Fremeaux-Bacchi V, Gale DP, van den Heuvel LP, Kavanagh D, Noris M, Pinto S, Rallapalli PM, Remuzzi G, Rodriguez de Cordoba S, Ruiz A, Smith RJH, Vieira-Martins P, Volokhina E, Wilson V, Goodship THJ, Perkins SJ (2018) Statistical validation of rare complement variants provides insights into the molecular basis of atypical hemolytic uremic syndrome and C3 glomerulopathy. J Immunol 200:2464\u20132478","journal-title":"J Immunol"},{"key":"7537_CR133","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1681\/ASN.2004050380","volume":"16","author":"MA Dragon-Durey","year":"2005","unstructured":"Dragon-Durey MA, Loirat C, Cloarec S, Macher MA, Blouin J, Nivet H, Weiss L, Fridman WH, Fremeaux-Bacchi V (2005) Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 16:555\u2013563","journal-title":"J Am Soc Nephrol"},{"key":"7537_CR134","doi-asserted-by":"crossref","unstructured":"Sinha A, Gulati A, Saini S, Blanc C, Gupta A, Gurjar BS, Saini H, Kotresh ST, Ali U, Bhatia D, Ohri A, Kumar M, Agarwal I, Gulati S, Anand K, Vijayakumar M, Sinha R, Sethi S, Salmona M, ..., Indian HUSR (2014) Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. Kidney Int 85:1151\u20131160","DOI":"10.1038\/ki.2013.373"},{"key":"7537_CR135","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s00467-016-3562-7","volume":"32","author":"D Song","year":"2017","unstructured":"Song D, Liu XR, Chen Z, Xiao HJ, Ding J, Sun SZ, Liu HY, Guo WY, Wang SX, Yu F, Zhao MH, Chinese Renal TMANI (2017) The clinical and laboratory features of Chinese Han anti-factor H autoantibody-associated hemolytic uremic syndrome. Pediatr Nephrol 32:811\u2013822","journal-title":"Pediatr Nephrol"},{"key":"7537_CR136","doi-asserted-by":"publisher","first-page":"6904858","DOI":"10.1155\/2021\/6904858","volume":"2021","author":"S Shawky","year":"2021","unstructured":"Shawky S, Safouh H, Gamal M, Abbas MM, Aboul-Enein A, Sawai T, Fahmy Y, Selim H (2021) Anti-factor H antibodies in egyptian children with hemolytic uremic syndrome. Int J Nephrol 2021:6904858","journal-title":"Int J Nephrol"},{"key":"7537_CR137","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2215\/CJN.01260212","volume":"8","author":"J Hofer","year":"2013","unstructured":"Hofer J, Janecke AR, Zimmerhackl LB, Riedl M, Rosales A, Giner T, Cortina G, Haindl CJ, Petzelberger B, Pawlik M, Jeller V, Vester U, Gadner B, van Husen M, Moritz ML, Wurzner R, Jungraithmayr T, German-Austrian HUSSG (2013) Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 8:407\u2013415","journal-title":"Clin J Am Soc Nephrol"},{"key":"7537_CR138","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nrneph.2016.99","volume":"12","author":"MA Durey","year":"2016","unstructured":"Durey MA, Sinha A, Togarsimalemath SK, Bagga A (2016) Anti-complement-factor H-associated glomerulopathies. Nat Rev Nephrol 12:563\u2013578","journal-title":"Nat Rev Nephrol"},{"key":"7537_CR139","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.imbio.2013.06.004","volume":"219","author":"R Watson","year":"2014","unstructured":"Watson R, Lindner S, Bordereau P, Hunze EM, Tak F, Ngo S, Zipfel PF, Skerka C, Dragon-Durey MA, Marchbank KJ (2014) Standardisation of the factor H autoantibody assay. Immunobiology 219:9\u201316","journal-title":"Immunobiology"},{"key":"7537_CR140","doi-asserted-by":"publisher","first-page":"853","DOI":"10.3389\/fimmu.2019.00853","volume":"10","author":"E Valoti","year":"2019","unstructured":"Valoti E, Alberti M, Iatropoulos P, Piras R, Mele C, Breno M, Cremaschi A, Bresin E, Donadelli R, Alizzi S, Amoroso A, Benigni A, Remuzzi G, Noris M (2019) Rare functional variants in complement genes and anti-FH autoantibodies-associated aHUS. Front Immunol 10:853","journal-title":"Front Immunol"},{"key":"7537_CR141","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s00467-020-04751-9","volume":"36","author":"J Hofer","year":"2021","unstructured":"Hofer J, Riedl Khursigara M, Perl M, Giner T, Rosales A, Cortina G, Waldegger S, Jungraithmayr T, Wurzner R (2021) Early relapse rate determines further relapse risk: results of a 5-year follow-up study on pediatric CFH-Ab HUS. Pediatr Nephrol 36:917\u2013925","journal-title":"Pediatr Nephrol"},{"key":"7537_CR142","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1007\/s00467-021-05390-4","volume":"37","author":"P Khandelwal","year":"2022","unstructured":"Khandelwal P, Krishnasamy S, Govindarajan S, Kumar M, Marik B, Sinha A, Hari P, Bagga A (2022) Anti-factor H antibody associated hemolytic uremic syndrome following SARS-CoV-2 infection. Pediatr Nephrol 37:2151\u20132156","journal-title":"Pediatr Nephrol"},{"key":"7537_CR143","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1007\/s00467-022-05862-1","volume":"38","author":"P Khandelwal","year":"2023","unstructured":"Khandelwal P, Joshi A, Mathur A, Puraswani M, Gurjar BS, Sinha A, Hari P, Faruq M, Bagga A (2023) Variants in complement genes are uncommon in patients with anti-factor H autoantibody-associated atypical hemolytic uremic syndrome. Pediatr Nephrol 38:2659\u20132668","journal-title":"Pediatr Nephrol"},{"key":"7537_CR144","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s00467-014-2948-7","volume":"30","author":"P Khandelwal","year":"2015","unstructured":"Khandelwal P, Gupta A, Sinha A, Saini S, Hari P, Dragon Durey MA, Bagga A (2015) Effect of plasma exchange and immunosuppressive medications on antibody titers and outcome in anti-complement factor H antibody-associated hemolytic uremic syndrome. Pediatr Nephrol 30:451\u2013457","journal-title":"Pediatr Nephrol"},{"key":"7537_CR145","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1007\/s00467-021-05025-8","volume":"36","author":"L Matrat","year":"2021","unstructured":"Matrat L, Bacchetta J, Ranchin B, Tann\u00e9 C, Sellier-Leclerc AL (2021) Pediatric atypical hemolytic-uremic syndrome due to auto-antibodies against factor H: is there an interest to combine eculizumab and mycophenolate mofetil? Pediatr Nephrol 36:1647\u20131650","journal-title":"Pediatr Nephrol"},{"key":"7537_CR146","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1007\/s00467-024-06373-x","volume":"39","author":"M Ferri","year":"2024","unstructured":"Ferri M, Zotta F, Donadelli R, Dossier C, Duneton C, El-Sissy C, Fremeau-Bacchi V, Kwon T, Quadri L, Pasini A, Sellier-Leclerc AL, Vivarelli M, Hogan J (2024) Anti-CFH-associated hemolytic uremic syndrome: do we still need plasma exchange? Pediatr Nephrol 39:3263\u20133269","journal-title":"Pediatr Nephrol"},{"key":"7537_CR147","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1007\/s00467-021-05025-8","volume":"36","author":"L Matrat","year":"2021","unstructured":"Matrat L, Bacchetta J, Ranchin B, Tanne C, Sellier-Leclerc AL (2021) Pediatric atypical hemolytic-uremic syndrome due to auto-antibodies against factor H: is there an interest to combine eculizumab and mycophenolate mofetil? Pediatr Nephrol 36:1647\u20131650","journal-title":"Pediatr Nephrol"},{"key":"7537_CR148","doi-asserted-by":"crossref","unstructured":"Trautmann A, Vivarelli M, Samuel S, Gipson D, Sinha A, Schaefer F, Hui NK, Boyer O, Saleem MA, Feltran L, Muller-Deile J, Becker JU, Cano F, Xu H, Lim YN, Smoyer W, Anochie I, Nakanishi K, Hodson E, International Pediatric Nephrology A (2020) IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 35:1529\u20131561","DOI":"10.1007\/s00467-020-04519-1"},{"key":"7537_CR149","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1007\/s00467-024-06374-w","volume":"39","author":"P Khandelwal","year":"2024","unstructured":"Khandelwal P, Bagga A (2024) Managing anti-factor H antibody-associated hemolytic uremic syndrome: time for consensus. Pediatr Nephrol 39:3137\u20133141","journal-title":"Pediatr Nephrol"},{"key":"7537_CR150","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s00467-024-06530-2","volume":"40","author":"PA Coccia","year":"2025","unstructured":"Coccia PA, Alconcher LF, Ferraris V, Lucarelli LI, Grillo MA, Arias MA, Saurit M, Ratto VM, Dos Santos C, Sanchez-Luceros A (2025) Eculizumab as first-line treatment for patients with severe presentation of complement factor H antibody-mediated hemolytic uremic syndrome. Pediatr Nephrol 40:1041\u20131047","journal-title":"Pediatr Nephrol"},{"key":"7537_CR151","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00467-013-2654-x","volume":"29","author":"D Noone","year":"2014","unstructured":"Noone D, Waters A, Pluthero FG, Geary DF, Kirschfink M, Zipfel PF, Licht C (2014) Successful treatment of DEAP-HUS with eculizumab. Pediatr Nephrol 29:841\u2013851","journal-title":"Pediatr Nephrol"},{"key":"7537_CR152","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1007\/s00431-020-03666-9","volume":"179","author":"S Stolbova","year":"2020","unstructured":"Stolbova S, Bezdicka M, Seeman T, Prohaszka Z, Csuka D, Hrachovinova I, Burkert J, Simankova N, Pruhova S, Zieg J (2020) Molecular basis and outcomes of atypical haemolytic uraemic syndrome in Czech children. Eur J Pediatr 179:1739\u20131750","journal-title":"Eur J Pediatr"},{"key":"7537_CR153","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/jca.21711","volume":"34","author":"P Khandelwal","year":"2019","unstructured":"Khandelwal P, Thomas CC, Rathi BS, Hari P, Tiwari AN, Sinha A, Bagga A (2019) Membrane-filtration based plasma exchanges for atypical hemolytic uremic syndrome: audit of efficacy and safety. J Clin Apher 34:555\u2013562","journal-title":"J Clin Apher"},{"key":"7537_CR154","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1053\/j.ajkd.2009.12.026","volume":"55","author":"O Boyer","year":"2010","unstructured":"Boyer O, Balzamo E, Charbit M, Biebuyck-Gouge N, Salomon R, Dragon-Durey MA, Fremeaux-Bacchi V, Niaudet P (2010) Pulse cyclophosphamide therapy and clinical remission in atypical hemolytic uremic syndrome with anti-complement factor H autoantibodies. Am J Kidney Dis 55:923\u2013927","journal-title":"Am J Kidney Dis"},{"key":"7537_CR155","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000018308","volume":"98","author":"J Lu","year":"2019","unstructured":"Lu J, Zhang L, Xia C, Tao Y (2019) Complications of therapeutic plasma exchange: a retrospective study of 1201 procedures in 435 children. Medicine (Baltimore) 98:e18308","journal-title":"Medicine (Baltimore)"},{"key":"7537_CR156","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s13730-020-00555-w","volume":"10","author":"S Govindarajan","year":"2021","unstructured":"Govindarajan S, Ramachandran R, Rawat A, Naganur SH, Nada R, Dawman L, Kumar A, Tiewsoh K (2021) Pericardial effusion in anti-complement factor H antibody-associated atypical hemolytic uremic syndrome: two case reports. CEN Case Rep 10:255\u2013260","journal-title":"CEN Case Rep"},{"key":"7537_CR157","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00467-013-2558-9","volume":"29","author":"G Sana","year":"2014","unstructured":"Sana G, Dragon-Durey MA, Charbit M, Bouchireb K, Rousset-Rouviere C, Berard E, Salomon R, Fremeaux-Bacchi V, Niaudet P, Boyer O (2014) Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses. Pediatr Nephrol 29:75\u201383","journal-title":"Pediatr Nephrol"},{"key":"7537_CR158","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1093\/ndt\/gfp388","volume":"25","author":"S Strobel","year":"2010","unstructured":"Strobel S, Hoyer PF, Mache CJ, Sulyok E, Liu WS, Richter H, Oppermann M, Zipfel PF, Jozsi M (2010) Functional analyses indicate a pathogenic role of factor H autoantibodies in atypical haemolytic uraemic syndrome. Nephrol Dial Transplant 25:136\u2013144","journal-title":"Nephrol Dial Transplant"},{"key":"7537_CR159","doi-asserted-by":"publisher","first-page":"49","DOI":"10.5414\/CN107777","volume":"83","author":"JJ Kim","year":"2015","unstructured":"Kim JJ, McCulloch M, Marks SD, Waters A, Noone D (2015) The clinical spectrum of hemolytic uremic syndrome secondary to complement factor H autoantibodies. Clin Nephrol 83:49\u201356","journal-title":"Clin Nephrol"},{"key":"7537_CR160","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.2215\/CJN.00320116","volume":"11","author":"S Tellier","year":"2016","unstructured":"Tellier S, Dallocchio A, Guigonis V, Saint-Marcoux F, Llanas B, Ichay L, Bandin F, Godron A, Morin D, Brochard K, Gandia P, Bouchet S, Marquet P, Decramer S, Harambat J (2016) Mycophenolic acid pharmacokinetics and relapse in children with steroid-dependent idiopathic nephrotic syndrome. Clin J Am Soc Nephrol 11:1777\u20131782","journal-title":"Clin J Am Soc Nephrol"},{"key":"7537_CR161","doi-asserted-by":"crossref","unstructured":"Zuber J, Le Quintrec M, Krid S, Bertoye C, Gueutin V, Lahoche A, Heyne N, Ardissino G, Chatelet V, Noel LH, Hourmant M, Niaudet P, Fremeaux-Bacchi V, Rondeau E, Legendre C, Loirat C, French Study Group for Atypical HUS (2012) Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant 12:3337\u20133354","DOI":"10.1111\/j.1600-6143.2012.04252.x"},{"key":"7537_CR162","doi-asserted-by":"publisher","first-page":"E134","DOI":"10.1111\/petr.12273","volume":"18","author":"P Khandelwal","year":"2014","unstructured":"Khandelwal P, Sinha A, Hari P, Bansal VK, Dinda AK, Bagga A (2014) Outcomes of renal transplant in patients with anti-complement factor H antibody-associated hemolytic uremic syndrome. Pediatr Transplant 18:E134-139","journal-title":"Pediatr Transplant"},{"key":"7537_CR163","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/nrneph.2010.155","volume":"7","author":"J Zuber","year":"2011","unstructured":"Zuber J, Le Quintrec M, Sberro-Soussan R, Loirat C, Fremeaux-Bacchi V, Legendre C (2011) New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol 7:23\u201335","journal-title":"Nat Rev Nephrol"},{"key":"7537_CR164","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/ajt.12077","volume":"13","author":"M Le Quintrec","year":"2013","unstructured":"Le Quintrec M, Zuber J, Moulin B, Kamar N, Jablonski M, Lionet A, Chatelet V, Mousson C, Mourad G, Bridoux F, Cassuto E, Loirat C, Rondeau E, Delahousse M, Fremeaux-Bacchi V (2013) Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant 13:663\u2013675","journal-title":"Am J Transplant"},{"key":"7537_CR165","doi-asserted-by":"crossref","unstructured":"Zuber J, Frimat M, Caillard S, Kamar N, Gatault P, Petitprez F, Couzi L, Jourde-Chiche N, Chatelet V, Gaisne R, Bertrand D, Bamoulid J, Louis M, Sberro Soussan R, Navarro D, Westeel PF, Frimat L, Colosio C, Thierry A, ..., Fremeaux-Bacchi V (2019) Use of highly individualized complement blockade has revolutionized clinical outcomes after kidney transplantation and renal epidemiology of atypical hemolytic uremic syndrome. J Am Soc Nephrol 30:2449\u20132463","DOI":"10.1681\/ASN.2019040331"},{"key":"7537_CR166","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1681\/ASN.2012090884","volume":"24","author":"E Bresin","year":"2013","unstructured":"Bresin E, Rurali E, Caprioli J, Sanchez-Corral P, Fremeaux-Bacchi V, Rodriguez de Cordoba S, Pinto S, Goodship TH, Alberti M, Ribes D, Valoti E, Remuzzi G, Noris M, European Working Party on Complement Genetics in Renal D (2013) Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol 24:475\u2013486","journal-title":"J Am Soc Nephrol"},{"key":"7537_CR167","doi-asserted-by":"crossref","unstructured":"Vivarelli M, Barratt J, Beck LH, Jr., Fakhouri F, Gale DP, Goicoechea de Jorge E, Mosca M, Noris M, Pickering MC, Susztak K, Thurman JM, Cheung M, King JM, Jadoul M, Winkelmayer WC, Smith RJH, for Conference P (2024) The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 106:369\u2013391","DOI":"10.1016\/j.kint.2024.05.015"},{"key":"7537_CR168","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/ki.2009.472","volume":"77","author":"F Bienaime","year":"2010","unstructured":"Bienaime F, Dragon-Durey MA, Regnier CH, Nilsson SC, Kwan WH, Blouin J, Jablonski M, Renault N, Rameix-Welti MA, Loirat C, Sautes-Fridman C, Villoutreix BO, Blom AM, Fremeaux-Bacchi V (2010) Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. Kidney Int 77:339\u2013349","journal-title":"Kidney Int"},{"key":"7537_CR169","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1053\/j.ajkd.2017.08.005","volume":"70","author":"M Noris","year":"2017","unstructured":"Noris M, Ruggenenti P, Remuzzi G (2017) Kidney transplantation in patients with atypical hemolytic uremic syndrome: a therapeutic dilemma (or not)? Am J Kidney Dis 70:754\u2013757","journal-title":"Am J Kidney Dis"},{"key":"7537_CR170","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.kint.2019.01.043","volume":"95","author":"M Praga","year":"2019","unstructured":"Praga M, Rodriguez de Cordoba S (2019) Secondary atypical hemolytic uremic syndromes in the era of complement blockade. Kidney Int 95:1298\u20131300","journal-title":"Kidney Int"},{"key":"7537_CR171","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1034\/j.1600-6143.2003.00051.x","volume":"3","author":"M Robson","year":"2003","unstructured":"Robson M, Cote I, Abbs I, Koffman G, Goldsmith D (2003) Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage? Am J Transplant 3:324\u2013327","journal-title":"Am J Transplant"},{"key":"7537_CR172","first-page":"27","volume":"33","author":"JM Campistol","year":"2013","unstructured":"Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa M, Grinyo JM, Praga M, Torra R, Vilalta R, Rodriguez de Cordoba S (2013) An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia 33:27\u201345","journal-title":"Nefrologia"},{"key":"7537_CR173","doi-asserted-by":"publisher","first-page":"e13371","DOI":"10.1111\/ctr.13371","volume":"32","author":"E Gavriilaki","year":"2018","unstructured":"Gavriilaki E, Sakellari I, Batsis I, Mallouri D, Bousiou Z, Vardi A, Yannaki E, Constantinou V, Tsompanakou A, Vadikoliou C, Kaloyannidis P, Bamihas G, Anagnostopoulos A (2018) Transplant-associated thrombotic microangiopathy: Incidence, prognostic factors, morbidity, and mortality in allogeneic hematopoietic cell transplantation. Clin Transplant 32:e13371","journal-title":"Clin Transplant"},{"key":"7537_CR174","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1056\/NEJMc1001060","volume":"362","author":"LB Zimmerhackl","year":"2010","unstructured":"Zimmerhackl LB, Hofer J, Cortina G, Mark W, Wurzner R, Jungraithmayr TC, Khursigara G, Kliche KO, Radauer W (2010) Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N Engl J Med 362:1746\u20131748","journal-title":"N Engl J Med"},{"issue":"7","key":"7537_CR175","doi-asserted-by":"publisher","first-page":"919","DOI":"10.3390\/jcm8070919","volume":"8","author":"ML Gonzalez Suarez","year":"2019","unstructured":"Gonzalez Suarez ML, Thongprayoon C, Mao MA, Leeaphorn N, Bathini T, Cheungpasitporn W (2019) Outcomes of kidney transplant patients with atypical hemolytic uremic syndrome treated with eculizumab: a systematic review and meta-analysis. J Clin Med 8(7):919. https:\/\/doi.org\/10.3390\/jcm8070919","journal-title":"J Clin Med"},{"key":"7537_CR176","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.transproceed.2021.09.063","volume":"54","author":"CC Gonzalez","year":"2022","unstructured":"Gonzalez CC, Lopez-Jimenez V, Vazquez-Sanchez T, Vazquez-Sanchez E, Cabello M, Hernandez-Marrero D (2022) Efficacy and safety of eculizumab in kidney transplant patients with primary atypical hemolytic-uremic syndrome. Transplant Proc 54:25\u201326","journal-title":"Transplant Proc"},{"key":"7537_CR177","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1093\/ckj\/sfaa096","volume":"14","author":"J Portoles","year":"2021","unstructured":"Portoles J, Huerta A, Arjona E, Gavela E, Aguera M, Jimenez C, Cavero T, Marrero D, Rodriguez de Cordoba S, Diekmann F, Matrix I (2021) Characteristics, management and outcomes of atypical haemolytic uraemic syndrome in kidney transplant patients: a retrospective national study. Clin Kidney J 14:1173\u20131180","journal-title":"Clin Kidney J"},{"key":"7537_CR178","doi-asserted-by":"publisher","first-page":"e0227445","DOI":"10.1371\/journal.pone.0227445","volume":"15","author":"CM Teixeira","year":"2020","unstructured":"Teixeira CM, Tedesco Silva Junior H, Moura LAR, Proenca HMS, de Marco R, Gerbase de Lima M, Cristelli MP, Viana LA, Felipe CR, Medina Pestana JO (2020) Clinical and pathological features of thrombotic microangiopathy influencing long-term kidney transplant outcomes. PLoS ONE 15:e0227445","journal-title":"PLoS ONE"},{"key":"7537_CR179","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1111\/j.1600-6143.2010.03178.x","volume":"10","author":"AA Satoskar","year":"2010","unstructured":"Satoskar AA, Pelletier R, Adams P, Nadasdy GM, Brodsky S, Pesavento T, Henry M, Nadasdy T (2010) De novo thrombotic microangiopathy in renal allograft biopsies-role of antibody-mediated rejection. Am J Transplant 10:1804\u20131811","journal-title":"Am J Transplant"},{"key":"7537_CR180","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1111\/j.1600-6143.2008.02297.x","volume":"8","author":"M Le Quintrec","year":"2008","unstructured":"Le Quintrec M, Lionet A, Kamar N, Karras A, Barbier S, Buchler M, Fakhouri F, Provost F, Fridman WH, Thervet E, Legendre C, Zuber J, Fremeaux-Bacchi V (2008) Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant 8:1694\u20131701","journal-title":"Am J Transplant"},{"key":"7537_CR181","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1093\/ndt\/gfh929","volume":"20","author":"CM Wyatt","year":"2005","unstructured":"Wyatt CM, Dikman S, Sehgal V, Murphy BT, Bromberg JS, Ames S, Akalin E (2005) Chronic organizing microangiopathy in a renal transplant recipient. Nephrol Dial Transplant 20:1734\u20131737","journal-title":"Nephrol Dial Transplant"},{"key":"7537_CR182","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.transproceed.2013.12.022","volume":"46","author":"N Larpparisuth","year":"2014","unstructured":"Larpparisuth N, Vongwiwatana A, Vareesangthip K, Cheunsuchon B, Parichatikanon P, Premasathian N (2014) Clinicopathologic features and treatment response of early acute antibody-mediated rejection in Thai kidney transplant recipients: a single-center experience. Transplant Proc 46:474\u2013476","journal-title":"Transplant Proc"},{"key":"7537_CR183","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1505533","volume":"374","author":"F Peyvandi","year":"2016","unstructured":"Peyvandi F, Scully M, Kremer Hovinga JA, Cataland S, Knobl P, Wu H, Artoni A, Westwood JP, Mansouri Taleghani M, Jilma B, Callewaert F, Ulrichts H, Duby C, Tersago D, Investigators T (2016) Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med 374:511\u2013522","journal-title":"N Engl J Med"},{"key":"7537_CR184","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/his.13855","volume":"75","author":"V Broecker","year":"2019","unstructured":"Broecker V, Bardsley V, Torpey N, Perera R, Montero R, Dorling A, Bentall A, Neil D, Willicombe M, Berry M, Roufosse C (2019) Clinical-pathological correlations in post-transplant thrombotic microangiopathy. Histopathology 75:88\u2013103","journal-title":"Histopathology"},{"key":"7537_CR185","doi-asserted-by":"publisher","first-page":"160","DOI":"10.4103\/1319-2442.279936","volume":"31","author":"LP Saikumar Doradla","year":"2020","unstructured":"Saikumar Doradla LP, Lal H, Kaul A, Bhaduaria D, Jain M, Prasad N, Thammishetti V, Gupta A, Patel M, Sharma RK (2020) Clinical profile and outcomes of de novo posttransplant thrombotic microangiopathy. Saudi J Kidney Dis Transpl 31:160\u2013168","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"7537_CR186","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1016\/j.transproceed.2012.07.039","volume":"44","author":"RA Caires","year":"2012","unstructured":"Caires RA, Marques ID, Repizo LP, Sato VA, Carmo LP, Machado DJ, de Paula FJ, Nahas WC, David-Neto E (2012) De novo thrombotic microangiopathy after kidney transplantation: clinical features, treatment, and long-term patient and graft survival. Transplant Proc 44:2388\u20132390","journal-title":"Transplant Proc"},{"key":"7537_CR187","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1016\/j.transproceed.2005.02.112","volume":"37","author":"A Bren","year":"2005","unstructured":"Bren A, Pajek J, Grego K, Buturovic J, Ponikvar R, Lindic J, Knap B, Vizjak A, Ferluga D, Kandus A (2005) Follow-up of kidney graft recipients with cyclosporine-associated hemolytic-uremic syndrome and thrombotic microangiopathy. Transplant Proc 37:1889\u20131891","journal-title":"Transplant Proc"},{"key":"7537_CR188","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s10157-008-0037-6","volume":"12","author":"M Saito","year":"2008","unstructured":"Saito M, Satoh S, Kagaya H, Tsuruta H, Obara T, Kumazawa T, Inoue T, Inoue K, Miura M, Yuasa T, Komatsuda A, Tsuchiya N, Habuchi T (2008) Thrombotic microangiopathy developing in early stage after renal transplantation with a high trough level of tacrolimus. Clin Exp Nephrol 12:312\u2013315","journal-title":"Clin Exp Nephrol"},{"key":"7537_CR189","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.transproceed.2010.03.083","volume":"42","author":"V Rizza","year":"2010","unstructured":"Rizza V, Coletti G, Mazzotta C, Clemente K, Di Cocco P, Del Reno F, Margiotta G, Famulari A, Pisani F (2010) A rare case of colic thrombotic microangiopathy in renal transplantation. Transplant Proc 42:1362\u20131364","journal-title":"Transplant Proc"},{"key":"7537_CR190","doi-asserted-by":"publisher","first-page":"24","DOI":"10.4103\/0971-4065.125052","volume":"24","author":"S Radha","year":"2014","unstructured":"Radha S, Tameem A, Sridhar G, Aiyangar A, Rajaram KG, Prasad R, Kiran K (2014) Thrombotic microangiopathy in renal allografts. Indian J Nephrol 24:24\u201327","journal-title":"Indian J Nephrol"},{"key":"7537_CR191","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1177\/1076029615599439","volume":"23","author":"P Dhakal","year":"2017","unstructured":"Dhakal P, Giri S, Pathak R, Bhatt VR (2017) Eculizumab in transplant-associated thrombotic microangiopathy. Clin Appl Thromb Hemost 23:175\u2013180","journal-title":"Clin Appl Thromb Hemost"},{"key":"7537_CR192","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.jogc.2020.10.018","volume":"43","author":"V Cherniak","year":"2021","unstructured":"Cherniak V, Demir KK, Sandal S, Cantarovich M, Podymow T, Naessens V, Ponette V, Wou K, Do AT, Malhame I (2021) Thrombotic microangiopathy in a pregnant woman with kidney transplantation: a case report. J Obstet Gynaecol Can 43:874\u2013878","journal-title":"J Obstet Gynaecol Can"},{"key":"7537_CR193","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1093\/ndt\/17.8.1524","volume":"17","author":"C Edwards","year":"2002","unstructured":"Edwards C, House A, Shahinian V, Knoll G (2002) Sirolimus-based immunosuppression for transplant-associated thrombotic microangiopathy. Nephrol Dial Transplant 17:1524\u20131526","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 12","key":"7537_CR194","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1399-0012.2004.00220.x","volume":"18","author":"AK Sundberg","year":"2004","unstructured":"Sundberg AK, Rohr MS, Hartmann EL, Adams PL, Stratta RJ (2004) Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients. Clin Transplant 18(Suppl 12):61\u201366","journal-title":"Clin Transplant"},{"key":"7537_CR195","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/ctr.12170","volume":"27","author":"S Koppula","year":"2013","unstructured":"Koppula S, Yost SE, Sussman A, Bracamonte ER, Kaplan B (2013) Successful conversion to belatacept after thrombotic microangiopathy in kidney transplant patients. Clin Transplant 27:591\u2013597","journal-title":"Clin Transplant"},{"key":"7537_CR196","doi-asserted-by":"publisher","first-page":"10228","DOI":"10.3389\/ti.2022.10228","volume":"35","author":"A Morel","year":"2022","unstructured":"Morel A, Hoisnard L, Dudreuilh C, Moktefi A, Kheav D, Pimentel A, Sakhi H, Mokrani D, Attias P, El Sakhawi K, Champy CM, Remy P, Sbidian E, Grimbert P, Matignon M (2022) Three-year outcomes in kidney transplant recipients switched from calcineurin inhibitor-based regimens to belatacept as a rescue therapy. Transpl Int 35:10228","journal-title":"Transpl Int"},{"key":"7537_CR197","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1046\/j.1523-1755.1999.00492.x","volume":"55","author":"A Zarifian","year":"1999","unstructured":"Zarifian A, Meleg-Smith S, O\u2019Donovan R, Tesi RJ, Batuman V (1999) Cyclosporine-associated thrombotic microangiopathy in renal allografts. Kidney Int 55:2457\u20132466","journal-title":"Kidney Int"},{"key":"7537_CR198","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.trre.2017.10.001","volume":"32","author":"N Garg","year":"2018","unstructured":"Garg N, Rennke HG, Pavlakis M, Zandi-Nejad K (2018) De novo thrombotic microangiopathy after kidney transplantation. Transplant Rev 32:58\u201368","journal-title":"Transplant Rev"},{"key":"7537_CR199","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ekir.2020.10.009","volume":"6","author":"LMP Palma","year":"2021","unstructured":"Palma LMP, Sridharan M, Sethi S (2021) Complement in secondary thrombotic microangiopathy. Kidney Int Rep 6:11\u201323","journal-title":"Kidney Int Rep"},{"key":"7537_CR200","doi-asserted-by":"publisher","first-page":"891513","DOI":"10.3389\/fmed.2023.891513","volume":"10","author":"CW Teoh","year":"2023","unstructured":"Teoh CW, Riedl Khursigara M, Ortiz-Sandoval CG, Park JW, Li J, Bohorquez-Hernandez A, Bruno V, Bowen EE, Freeman SA, Robinson LA, Licht C (2023) The loss of glycocalyx integrity impairs complement factor H binding and contributes to cyclosporine-induced endothelial cell injury. Front Med (Lausanne) 10:891513","journal-title":"Front Med (Lausanne)"},{"key":"7537_CR201","first-page":"761","volume":"4","author":"EE Bowen","year":"2023","unstructured":"Bowen EE, Hurcombe JA, Barrington F, Keir LS, Farmer LK, Wherlock MD, Ortiz-Sandoval CG, Bruno V, Bohorquez-Hernandez A, Diatlov D, Rostam-Shirazi N, Wells S, Stewart M, Teboul L, Lay AC, Butler MJ, Pope RJP, Larkai EMS, Morgan BP, Moppett J, Satchell SC, Welsh GI, Walker PD, Licht C, Saleem MA, Coward RJM (2023) Shiga toxin targets the podocyte causing hemolytic uremic syndrome through endothelial complement activation. Med (New York, NY) 4:761-777 e768","journal-title":"Med (New York, NY)"},{"key":"7537_CR202","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/j.kint.2019.01.023","volume":"95","author":"A Le Clech","year":"2019","unstructured":"Le Clech A, Simon-Tillaux N, Provot F, Delmas Y, Vieira-Martins P, Limou S, Halimi JM, Le Quintrec M, Lebourg L, Grange S, Karras A, Ribes D, Jourde-Chiche N, Rondeau E, Fremeaux-Bacchi V, Fakhouri F (2019) Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors. Kidney Int 95:1443\u20131452","journal-title":"Kidney Int"},{"key":"7537_CR203","first-page":"1073","volume":"365","author":"PI Tarr","year":"2005","unstructured":"Tarr PI, Gordon CA, Chandler WL (2005) Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet (London, England) 365:1073\u20131086","journal-title":"Lancet (London, England)"},{"key":"7537_CR204","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMc1100859","volume":"364","author":"AL Lapeyraque","year":"2011","unstructured":"Lapeyraque AL, Malina M, Fremeaux-Bacchi V, Boppel T, Kirschfink M, Oualha M, Proulx F, Clermont MJ, Le Deist F, Niaudet P, Schaefer F (2011) Eculizumab in severe Shiga-toxin-associated HUS. New Engl J Med 364:2561\u20132563","journal-title":"New Engl J Med"},{"key":"7537_CR205","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/dmcn.12161","volume":"55","author":"C Gitiaux","year":"2013","unstructured":"Gitiaux C, Krug P, Grevent D, Kossorotoff M, Poncet S, Eisermann M, Oualha M, Boddaert N, Salomon R, Desguerre I (2013) Brain magnetic resonance imaging pattern and outcome in children with haemolytic-uraemic syndrome and neurological impairment treated with eculizumab. Dev Med Child Neurol 55:758\u2013765","journal-title":"Dev Med Child Neurol"},{"key":"7537_CR206","doi-asserted-by":"crossref","unstructured":"Kielstein JT, Beutel G, Fleig S, Steinhoff J, Meyer TN, Hafer C, Kuhlmann U, Bramstedt J, Panzer U, Vischedyk M, Busch V, Ries W, Mitzner S, Mees S, Stracke S, Nurnberger J, Gerke P, Wiesner M, Sucke B, ..., Collaborators of the DS-HUSr (2012) Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transplant 27:3807\u20133815","DOI":"10.1093\/ndt\/gfs394"},{"key":"7537_CR207","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s00467-023-06216-1","volume":"39","author":"PL de Zwart","year":"2024","unstructured":"de Zwart PL, Mueller TF, Sparta G, Luyckx VA (2024) Eculizumab in Shiga toxin-producing Escherichia coli hemolytic uremic syndrome: a systematic review. Pediatr Nephrol 39:1369\u20131385","journal-title":"Pediatr Nephrol"},{"key":"7537_CR208","doi-asserted-by":"crossref","unstructured":"Garnier A, Brochard K, Kwon T, Sellier-Leclerc AL, Lahoche A, Launay EA, Nobili F, Caillez M, Taque S, Harambat J, Michel-Bourdat G, Guigonis V, Fila M, Cloarec S, Djamal-Dine D, de Parscaux L, Allard L, Salomon R, Ulinski T, ..., Brusq C (2023) Efficacy and safety of Eculizumab in pediatric patients affected by shiga toxin-related hemolytic and uremic syndrome: a randomized, placebo-controlled trial. J Am Soc Nephrol 34:1561\u20131573","DOI":"10.1681\/ASN.0000000000000182"},{"key":"7537_CR209","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1007\/s00467-017-3783-4","volume":"33","author":"M Bitzan","year":"2018","unstructured":"Bitzan M, Zieg J (2018) Influenza-associated thrombotic microangiopathies. Pediatr Nephrol 33:2009\u20132025","journal-title":"Pediatr Nephrol"},{"key":"7537_CR210","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.thromres.2021.04.012","volume":"202","author":"NR Tiwari","year":"2021","unstructured":"Tiwari NR, Phatak S, Sharma VR, Agarwal SK (2021) COVID-19 and thrombotic microangiopathies. Thromb Res 202:191\u2013198","journal-title":"Thromb Res"},{"key":"7537_CR211","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1186\/s12882-018-1168-y","volume":"19","author":"K Saida","year":"2018","unstructured":"Saida K, Ogura M, Kano Y, Ishimori S, Yoshikawa T, Nagata H, Sato M, Kamei K, Ishikura K (2018) Treatment of hemolytic uremic syndrome related to Bordetella pertussis infection -is plasma exchange or eculizumab use necessary? BMC Nephrol 19:365","journal-title":"BMC Nephrol"},{"key":"7537_CR212","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00467-018-4174-1","volume":"34","author":"I Madden","year":"2019","unstructured":"Madden I, Roumenina LT, Langlois-Meurinne H, Guichoux J, Llanas B, Fremeaux-Bacchi V, Harambat J, Godron-Dubrasquet A (2019) Hemolytic uremic syndrome associated with Bordetella pertussis infection in a 2-month-old infant carrying a pathogenic variant in complement factor H. Pediatr Nephrol 34:533\u2013537","journal-title":"Pediatr Nephrol"},{"key":"7537_CR213","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s40620-020-00858-2","volume":"33","author":"R Mahajan","year":"2020","unstructured":"Mahajan R, Lipton M, Broglie L, Jain NG, Uy NS (2020) Eculizumab treatment for renal failure in a pediatric patient with COVID-19. J Nephrol 33:1373\u20131376","journal-title":"J Nephrol"},{"issue":"82\u201393","key":"7537_CR214","volume":"77","author":"S Akilesh","year":"2021","unstructured":"Akilesh S, Nast CC, Yamashita M, Henriksen K, Charu V, Troxell ML, Kambham N, Bracamonte E, Houghton D, Ahmed NI, Chong CC, Thajudeen B, Rehman S, Khoury F, Zuckerman JE, Gitomer J, Raguram PC, Mujeeb S, Schwarze U, Smith KD (2021) Multicenter clinicopathologic correlation of kidney biopsies performed in COVID-19 patients presenting with acute kidney injury or Proteinuria. Am J Kidney Dis 77(82\u201393):e81","journal-title":"Am J Kidney Dis"},{"key":"7537_CR215","doi-asserted-by":"publisher","first-page":"e0009790","DOI":"10.1371\/journal.pntd.0009790","volume":"15","author":"JL Coelho Junior","year":"2021","unstructured":"Coelho Junior JL, Israel KCP, Machado CEE, Muniz MPR, Gatto GC, Barros FHS, Cunha KA, de Lacerda MVG, Neves P, Silva GEB (2021) Thrombotic microangiopathy associated with arboviral infection: Report of 3 cases. PLoS Negl Trop Dis 15:e0009790","journal-title":"PLoS Negl Trop Dis"},{"key":"7537_CR216","doi-asserted-by":"publisher","first-page":"ytab386","DOI":"10.1093\/ehjcr\/ytab386","volume":"5","author":"D Utebay","year":"2021","unstructured":"Utebay D, Seeger H, Muller AMS, David S (2021) Complement inhibition for the treatment of COVID-19 triggered thrombotic microangiopathy with cardiac failure: a case report. Eur Heart J Case Rep 5:ytab386","journal-title":"Eur Heart J Case Rep"},{"key":"7537_CR217","doi-asserted-by":"publisher","first-page":"641656","DOI":"10.3389\/fimmu.2021.641656","volume":"12","author":"I Gomez Delgado","year":"2021","unstructured":"Gomez Delgado I, Corvillo F, Nozal P, Arjona E, Madrid A, Melgosa M, Bravo J, Szilagyi A, Csuka D, Veszeli N, Prohaszka Z, Sanchez-Corral P (2021) Complement genetic variants and FH desialylation in S. pneumoniae-haemolytic uraemic syndrome. Front Immunol 12:641656","journal-title":"Front Immunol"},{"key":"7537_CR218","doi-asserted-by":"publisher","first-page":"886","DOI":"10.3389\/fimmu.2019.00886","volume":"10","author":"F Corvillo","year":"2019","unstructured":"Corvillo F, Okroj M, Nozal P, Melgosa M, Sanchez-Corral P, Lopez-Trascasa M (2019) Nephritic factors: an overview of classification, diagnostic tools and clinical associations. Front Immunol 10:886","journal-title":"Front Immunol"},{"key":"7537_CR219","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1007\/s00467-021-04952-w","volume":"36","author":"J Holle","year":"2021","unstructured":"Holle J, Habbig S, Gratopp A, Mauritsch A, Muller D, Thumfart J (2021) Complement activation in children with Streptococcus pneumoniae associated hemolytic uremic syndrome. Pediatr Nephrol 36:1311\u20131315","journal-title":"Pediatr Nephrol"},{"key":"7537_CR220","doi-asserted-by":"crossref","unstructured":"Cavero T, Arjona E, Soto K, Caravaca-Fontan F, Rabasco C, Bravo L, de la Cerda F, Martin N, Blasco M, Avila A, Huerta A, Cabello V, Jarque A, Alcazar C, Fulladosa X, Carbayo J, Anaya S, Cobelo C, Ramos N, ..., Spanish Group for the Study of Glomerular D (2019) Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome. Kidney Int 96:995\u20131004","DOI":"10.1016\/j.kint.2019.05.014"},{"key":"7537_CR221","doi-asserted-by":"publisher","first-page":"136","DOI":"10.4103\/0971-4065.181462","volume":"27","author":"V Raghunathan","year":"2017","unstructured":"Raghunathan V, Sethi SK, Dragon-Durey MA, Dhaliwal M, Raina R, Jha P, Bansal SB, Kher V (2017) Targeting renin-angiotensin system in malignant hypertension in atypical hemolytic uremic syndrome. Indian J Nephrol 27:136\u2013140","journal-title":"Indian J Nephrol"},{"key":"7537_CR222","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s40620-016-0357-7","volume":"30","author":"A Asif","year":"2017","unstructured":"Asif A, Nayer A, Haas CS (2017) Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab. J Nephrol 30:347\u2013362","journal-title":"J Nephrol"},{"key":"7537_CR223","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1093\/ndt\/gfw453","volume":"32","author":"T Cavero","year":"2017","unstructured":"Cavero T, Rabasco C, Lopez A, Roman E, Avila A, Sevillano A, Huerta A, Rojas-Rivera J, Fuentes C, Blasco M, Jarque A, Garcia A, Mendizabal S, Gavela E, Macia M, Quintana LF, Maria Romera A, Borrego J, Arjona E, Praga M (2017) Eculizumab in secondary atypical haemolytic uraemic syndrome. Nephrol Dial Transplant 32:466\u2013474","journal-title":"Nephrol Dial Transplant"},{"key":"7537_CR224","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s40620-021-00981-8","volume":"35","author":"C Aigner","year":"2022","unstructured":"Aigner C, Gaggl M, Stemer G, Eder M, Bohmig G, Kain R, Prohaszka Z, Garam N, Csuka D, Sunder-Plassmann R, Piggott LC, Haninger-Vacariu N, Schmidt A, Sunder-Plassmann G (2022) Eculizumab use in a tertiary care nephrology center: data from the Vienna TMA cohort. J Nephrol 35:451\u2013461","journal-title":"J Nephrol"},{"key":"7537_CR225","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00467-014-2944-y","volume":"30","author":"R Coppo","year":"2015","unstructured":"Coppo R, Peruzzi L, Amore A, Martino S, Vergano L, Lastauka I, Schieppati A, Noris M, Tovo PA, Remuzzi G (2015) Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy. Pediatr Nephrol 30:167\u2013172","journal-title":"Pediatr Nephrol"},{"key":"7537_CR226","doi-asserted-by":"publisher","first-page":"e12584","DOI":"10.1097\/MD.0000000000012584","volume":"97","author":"P Rovere-Querini","year":"2018","unstructured":"Rovere-Querini P, Canti V, Erra R, Bianchi E, Slaviero G, D\u2019Angelo A, Rosa S, Candiani M, Castiglioni MT (2018) Eculizumab in a pregnant patient with laboratory onset of catastrophic antiphospholipid syndrome: A case report. Medicine (Baltimore) 97:e12584","journal-title":"Medicine (Baltimore)"},{"key":"7537_CR227","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/ckj\/sfv101","volume":"8","author":"CP Thomas","year":"2015","unstructured":"Thomas CP, Nester CM, Phan AC, Sharma M, Steele AL, Lenert PS (2015) Eculizumab for rescue of thrombotic microangiopathy in PM-Scl antibody-positive autoimmune overlap syndrome. Clin Kidney J 8:698\u2013701","journal-title":"Clin Kidney J"},{"key":"7537_CR228","doi-asserted-by":"publisher","first-page":"e4459","DOI":"10.1097\/MD.0000000000004459","volume":"95","author":"A Devresse","year":"2016","unstructured":"Devresse A, Aydin S, Le Quintrec M, Demoulin N, Stordeur P, Lambert C, Gastoldi S, Pirson Y, Jadoul M, Morelle J (2016) Complement activation and effect of eculizumab in scleroderma renal crisis. Medicine (Baltimore) 95:e4459","journal-title":"Medicine (Baltimore)"},{"key":"7537_CR229","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.2169\/internalmedicine.0512-17","volume":"57","author":"S Yamada","year":"2018","unstructured":"Yamada S, Yamashita H, Nakano M, Hatano H, Sasaki T, Takahashi Y, Kaneko H (2018) Thrombotic microangiopathy with polymyositis\/dermatomyositis: three case reports and a literature review. Internal medicine (Tokyo, Japan) 57:2259\u20132265","journal-title":"Internal medicine (Tokyo, Japan)"},{"key":"7537_CR230","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1182\/blood-2014-03-564997","volume":"124","author":"S Jodele","year":"2014","unstructured":"Jodele S, Davies SM, Lane A, Khoury J, Dandoy C, Goebel J, Myers K, Grimley M, Bleesing J, El-Bietar J, Wallace G, Chima RS, Paff Z, Laskin BL (2014) Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood 124:645\u2013653","journal-title":"Blood"},{"key":"7537_CR231","first-page":"1049","volume":"135","author":"S Jodele","year":"2020","unstructured":"Jodele S, Dandoy CE, Lane A, Laskin BL, Teusink-Cross A, Myers KC, Wallace G, Nelson A, Bleesing J, Chima RS, Hirsch R, Ryan TD, Benoit S, Mizuno K, Warren M, Davies SM (2020) Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab. Blood 135:1049\u20131057","journal-title":"Blood"},{"key":"7537_CR232","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.bbmt.2005.04.007","volume":"11","author":"C Cutler","year":"2005","unstructured":"Cutler C, Henry NL, Magee C, Li S, Kim HT, Alyea E, Ho V, Lee SJ, Soiffer R, Antin JH (2005) Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 11:551\u2013557","journal-title":"Biol Blood Marrow Transplant"},{"key":"7537_CR233","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1111\/bjh.16457","volume":"189","author":"N Epperla","year":"2020","unstructured":"Epperla N, Li A, Logan B, Fretham C, Chhabra S, Aljurf M, Chee L, Copelan E, Freytes CO, Hematti P, Lazarus HM, Litzow M, Nishihori T, Olsson RF, Prestidge T, Saber W, Wirk B, Yared JA, Loren A, Pasquini M (2020) Incidence, risk factors for and outcomes of transplant-associated thrombotic microangiopathy. Br J Haematol 189:1171\u20131181","journal-title":"Br J Haematol"},{"key":"7537_CR234","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.2169\/internalmedicine.42.1228","volume":"42","author":"Y Komeno","year":"2003","unstructured":"Komeno Y, Ogawa S, Ishida T, Takeuchi K, Tsujino S, Kurokawa M, Aoki K, Kanda Y, Chiba S, Motokura T, Fukayama M, Hirai H (2003) Ischemic colitis as a manifestation of thrombotic microangiopathy following bone marrow transplantation. Intern Med (Tokyo, Japan) 42:1228\u20131232","journal-title":"Intern Med (Tokyo, Japan)"},{"key":"7537_CR235","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1038\/sj.bmt.1704512","volume":"33","author":"T Nishida","year":"2004","unstructured":"Nishida T, Hamaguchi M, Hirabayashi N, Haneda M, Terakura S, Atsuta Y, Imagama S, Kanie T, Murata M, Taji H, Suzuki R, Morishita Y, Kodera Y (2004) Intestinal thrombotic microangiopathy after allogeneic bone marrow transplantation: a clinical imitator of acute enteric graft-versus-host disease. Bone Marrow Transplant 33:1143\u20131150","journal-title":"Bone Marrow Transplant"},{"key":"7537_CR236","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1046\/j.1365-2141.2002.03721.x","volume":"118","author":"T Ruutu","year":"2002","unstructured":"Ruutu T, Hermans J, Niederwieser D, Gratwohl A, Kiehl M, Volin L, Bertz H, Ljungman P, Spence D, Verdonck LF, Prentice HG, Bosi A, Du Toit CE, Brinch L, Apperley JF, Party ECLW (2002) Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 118:1112\u20131119","journal-title":"Br J Haematol"},{"key":"7537_CR237","doi-asserted-by":"publisher","first-page":"6107","DOI":"10.4081\/hr.2015.6107","volume":"7","author":"C Fernandez","year":"2015","unstructured":"Fernandez C, Lario A, Fores R, Cabrera R (2015) Eculizumab treatment in a patient with hematopoietic stem cell transplantation-associated thrombotic microangiopathy and steroid-refractory acute graft versus host disease. Hematol Rep 7:6107","journal-title":"Hematol Rep"},{"key":"7537_CR238","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.arcped.2018.09.011","volume":"25","author":"L Genere","year":"2018","unstructured":"Genere L, Bacchetta J, Bertrand Y, Javouhey E, Cheikh N, Sellier-Leclerc AL (2018) Eculizumab and thrombotic microangiopathy after hematopoietic stem cell transplantation: a report on its efficacy and safety in two pediatric patients. Arch Pediatr 25:485\u2013488","journal-title":"Arch Pediatr"},{"key":"7537_CR239","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41409-023-02161-7","volume":"59","author":"S Ito","year":"2024","unstructured":"Ito S, Saito A, Sakurai A, Watanabe K, Karakawa S, Miyamura T, Yokosuka T, Ueki H, Goto H, Yagasaki H, Kinoshita M, Ozeki M, Yokoyama N, Teranishi H (2024) Eculizumab treatment in paediatric patients diagnosed with aHUS after haematopoietic stem cell transplantation: a HSCT-TMA case series from Japanese aHUS post-marketing surveillance. Bone Marrow Transplant 59:315\u2013324","journal-title":"Bone Marrow Transplant"},{"key":"7537_CR240","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/ejh.13127","volume":"101","author":"J Rudoni","year":"2018","unstructured":"Rudoni J, Jan A, Hosing C, Aung F, Yeh J (2018) Eculizumab for transplant-associated thrombotic microangiopathy in adult allogeneic stem cell transplant recipients. Eur J Haematol 101:389\u2013398","journal-title":"Eur J Haematol"},{"key":"7537_CR241","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.564647","volume":"11","author":"R Zhang","year":"2020","unstructured":"Zhang R, Zhou M, Qi J, Miao W, Zhang Z, Wu D, Han Y (2020) Efficacy and safety of eculizumab in the treatment of transplant-associated thrombotic microangiopathy: a systematic review and meta-analysis. Front Immunol 11:564647","journal-title":"Front Immunol"},{"key":"7537_CR242","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1016\/j.transproceed.2020.08.040","volume":"52","author":"T Jarmolinski","year":"2020","unstructured":"Jarmolinski T, Rosa M, Puziewicz-Zmonarska A, Kalwak K (2020) Short course of Eculizumab may be effective in dialysis-dependent transplantation-associated thrombotic microangiopathy after hematopoietic stem cell transplantation: a case report. Transplant Proc 52:2544\u20132547","journal-title":"Transplant Proc"},{"key":"7537_CR243","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1128\/jb.162.2.626-632.1985","volume":"162","author":"NB Shoemaker","year":"1985","unstructured":"Shoemaker NB, Guthrie EP, Salyers AA, Gardner JF (1985) Evidence that the clindamycin-erythromycin resistance gene of Bacteroides plasmid pBF4 is on a transposable element. J Bacteriol 162:626\u2013632","journal-title":"J Bacteriol"},{"key":"7537_CR244","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","volume":"125","author":"ZL Al-Nouri","year":"2015","unstructured":"Al-Nouri ZL, Reese JA, Terrell DR, Vesely SK, George JN (2015) Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood 125:616\u2013618","journal-title":"Blood"},{"key":"7537_CR245","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1177\/1078155216628324","volume":"23","author":"G Garcia","year":"2017","unstructured":"Garcia G, Atallah JP (2017) Antineoplastic agents and thrombotic microangiopathy. J Oncol Pharm Pract 23:135\u2013142","journal-title":"J Oncol Pharm Pract"},{"key":"7537_CR246","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1093\/ndt\/gfac213","volume":"38","author":"A Decaestecker","year":"2023","unstructured":"Decaestecker A, Hamroun A, Provot F, Rondeau E, Faguer S, Sallee M, Titeca-Beauport D, Rebibou JM, Forestier A, Azar R, Deltombe C, Wynckel A, Grange S, Fremeaux Bacchi V, Cartery C (2023) Retrospective study of 59 cases of cancer-associated thrombotic microangiopathy: presentation and treatment characteristics. Nephrol Dial Transplant 38:913\u2013921","journal-title":"Nephrol Dial Transplant"},{"key":"7537_CR247","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jpeds.2020.11.054","volume":"231","author":"DH Chand","year":"2021","unstructured":"Chand DH, Zaidman C, Arya K, Millner R, Farrar MA, Mackie FE, Goedeker NL, Dharnidharka VR, Dandamudi R, Reyna SP (2021) Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: a case series. J Pediatr 231:265\u2013268","journal-title":"J Pediatr"},{"key":"7537_CR248","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.1182\/bloodadvances.2021006419","volume":"6","author":"J Guillou","year":"2022","unstructured":"Guillou J, de Pellegars A, Porcheret F, Fremeaux-Bacchi V, Allain-Launay E, Debord C, Denis M, Pereon Y, Barnerias C, Desguerre I, Roussey G, Mercier S (2022) Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy. Blood Adv 6:4266\u20134270","journal-title":"Blood Adv"},{"key":"7537_CR249","doi-asserted-by":"crossref","unstructured":"Salabarria SM, Corti M, Coleman KE, Wichman MB, Berthy JA, D'Souza P, Tifft CJ, Herzog RW, Elder ME, Shoemaker LR, Leon-Astudillo C, Tavakkoli F, Kirn DH, Schwartz JD, Byrne BJ (2024) Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies. J Clin Invest 134","DOI":"10.1172\/JCI173510"},{"issue":"9","key":"7537_CR250","doi-asserted-by":"publisher","first-page":"4226","DOI":"10.1016\/j.ymthe.2025.06.032","volume":"33","author":"BJ Byrne","year":"2025","unstructured":"Byrne BJ, Butterfield RJ, Shieh PB, Smith EC, Licht C, Binks M, Casinghino S, Delnomdedieu M, Ravindra KC, McDonnell T, Ryan K, Schulz M, Shen Q, Shi H, Sirivelu MP, Vaidya VS, Whiteley L, Levy DI (2025) Complement activation in a phase ib study of fordadistrogene movaparvovec for duchenne muscular dystrophy. Mol Ther 33(9):4226\u20134238. https:\/\/doi.org\/10.1016\/j.ymthe.2025.06.032","journal-title":"Mol Ther"},{"key":"7537_CR251","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1182\/blood.2020005221","volume":"136","author":"F Fakhouri","year":"2020","unstructured":"Fakhouri F, Scully M, Provot F, Blasco M, Coppo P, Noris M, Paizis K, Kavanagh D, Pene F, Quezada S, Hertig A, Kissling S, O\u2019Brien P, Delmas Y, Alberio L, Winer N, Veyradier A, Cataland S, Fremeaux-Bacchi V, Tsatsaris V (2020) Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group. Blood 136:2103\u20132117","journal-title":"Blood"},{"key":"7537_CR252","unstructured":"World Health Organization (2017) World Bank and WHO: Half the world lacks access to essential health services, 100 million still pushed into extreme poverty because of health expenses. Accessed from https:\/\/www.who.int\/news\/item\/13-12-2017-world-bank-and-who-half-the-world-lacks-access-to-essential-health-services-100-million-still-pushed-into-extreme-poverty-because-of-health-expenses"},{"key":"7537_CR253","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s40620-022-01282-4","volume":"35","author":"HS Nga","year":"2022","unstructured":"Nga HS, Palma LMP, Ernandes Neto M, Modelli de Andrade LG (2022) Eculizumab in low-middle income countries: how much does a life cost? J Nephrol 35:1255\u20131257","journal-title":"J Nephrol"},{"key":"7537_CR254","doi-asserted-by":"publisher","first-page":"604","DOI":"10.25259\/IJN_140_2025","volume":"35","author":"T Bindal","year":"2025","unstructured":"Bindal T, Sinha A, Bagga A (2025) Eculizumab for atypical hemolytic uremic syndrome: guidance for developing countries. Indian J Nephrol 35:604\u2013613","journal-title":"Indian J Nephrol"},{"issue":"3","key":"7537_CR255","doi-asserted-by":"publisher","first-page":"582","DOI":"10.3390\/microorganisms10030582","volume":"10","author":"CC Carbonari","year":"2022","unstructured":"Carbonari CC, Miliwebsky ES, Zolezzi G, Deza NL, Fittipaldi N, Manfredi E, Baschkier A, D\u2019Astek BA, Melano RG, Schesi C, Rivas M, Chinen I (2022) The importance of Shiga toxin-producing Escherichia coli O145:NM[H28]\/H28 infections in Argentina, 1998\u20132020. Microorganisms 10(3):582. https:\/\/doi.org\/10.3390\/microorganisms10030582","journal-title":"Microorganisms"},{"key":"7537_CR256","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/j.1744-313X.2011.01071.x","volume":"39","author":"N Leban","year":"2012","unstructured":"Leban N, Abarrategui-Garrido C, Fariza-Requejo E, Aminoso-Carbonero C, Pinto S, Chibani JB, Khelil AH, Sanchez-Corral P (2012) Factor H and CFHR1 polymorphisms associated with atypical Haemolytic Uraemic Syndrome (aHUS) are differently expressed in Tunisian and in Caucasian populations. Int J Immunogenet 39:110\u2013113","journal-title":"Int J Immunogenet"},{"key":"7537_CR257","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/nep.13217","volume":"24","author":"H Jlajla","year":"2019","unstructured":"Jlajla H, Dehman F, Jallouli M, Khedher R, Ayadi I, Zerzeri Y, Laadhar L, Sfar I, Mahfoudh A, Gorgi Y, Cheour E, Zouaghi K, Gargah T, Kallel Sellami M (2019) Molecular basis of complement factor I deficiency in Tunisian atypical haemolytic and uraemic syndrome patients. Nephrology (Carlton) 24:357\u2013364","journal-title":"Nephrology (Carlton)"},{"key":"7537_CR258","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s40259-025-00707-3","volume":"39","author":"JH Jang","year":"2025","unstructured":"Jang JH, Han B, Jung J, Russo P, Kulasekararaj AG (2025) The path to accessible care: development and impact of eculizumab biosimilars for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. BioDrugs 39:281\u2013295","journal-title":"BioDrugs"},{"key":"7537_CR259","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/jha2.632","volume":"4","author":"JH Jang","year":"2023","unstructured":"Jang JH, Gomez RD, Bumbea H, Nogaieva L, Wong LLL, Lim SM, Kim Y, Park J (2023) A phase III, randomised, double-blind, multi-national clinical trial comparing SB12 (proposed eculizumab biosimilar) and reference eculizumab in patients with paroxysmal nocturnal haemoglobinuria. EJHaem 4:26\u201336","journal-title":"EJHaem"},{"key":"7537_CR260","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1002\/ajh.27456","volume":"99","author":"A Kulasekararaj","year":"2024","unstructured":"Kulasekararaj A, Lanza F, Arvanitakis A, Langemeijer S, Chonat S, Tombak A, Hanes V, Cao J, Miller MJ, Colbert A, Shander B, Mytych DT, Chow V, Henary H (2024) Comparative clinical efficacy and safety of biosimilar ABP 959 and eculizumab reference product in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol 99:2108\u20132117","journal-title":"Am J Hematol"},{"key":"7537_CR261","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2215\/CJN.02170508","volume":"4","author":"JM Saland","year":"2009","unstructured":"Saland JM, Shneider BL, Bromberg JS, Shi PA, Ward SC, Magid MS, Benchimol C, Seikaly MG, Emre SH, Bresin E, Remuzzi G (2009) Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 4:201\u2013206","journal-title":"Clin J Am Soc Nephrol"},{"key":"7537_CR262","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1053\/j.ajkd.2011.04.008","volume":"58","author":"C Wilson","year":"2011","unstructured":"Wilson C, Torpey N, Jaques B, Strain L, Talbot D, Manas D, Goodship T (2011) Successful simultaneous liver-kidney transplant in an adult with atypical hemolytic uremic syndrome associated with a mutation in complement factor H. Am J Kidney Dis 58:109\u2013112","journal-title":"Am J Kidney Dis"},{"key":"7537_CR263","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.751093","volume":"12","author":"M Lopez-Trascasa","year":"2021","unstructured":"Lopez-Trascasa M, Alonso-Melgar A, Melgosa-Hijosa M, Espinosa-Roman L, Lledin-Barbancho MD, Garcia-Fernandez E, Rodriguez de Cordoba S, Sanchez-Corral P (2021) Case report: combined liver-kidney transplantation to correct a mutation in complement factor B in an atypical hemolytic uremic syndrome patient. Front Immunol 12:751093","journal-title":"Front Immunol"},{"key":"7537_CR264","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1681\/ASN.2008080906","volume":"20","author":"Saland JM, Ruggenenti P, Remuzzi G, Consensus Study G","year":"2009","unstructured":"Saland JM, Ruggenenti P, Remuzzi G, Consensus Study G (2009) Liver-kidney transplantation to cure atypical hemolytic uremic syndrome. J Am Soc Nephrol 20:940\u2013949","journal-title":"J Am Soc Nephrol"},{"key":"7537_CR265","doi-asserted-by":"crossref","unstructured":"Ravi R, Balan S, Murlidharan P, Visweswaran K, B V, T US, R S (2019) Isolated liver transplantation: a worthy choice for atypical hemolytic syndrome in resource-restricted settings. Kidney Int Rep 4:1019\u20131022","DOI":"10.1016\/j.ekir.2019.03.008"},{"key":"7537_CR266","doi-asserted-by":"publisher","first-page":"414","DOI":"10.2471\/BLT.17.206441","volume":"96","author":"VA Luyckx","year":"2018","unstructured":"Luyckx VA, Tonelli M, Stanifer JW (2018) The global burden of kidney disease and the sustainable development goals. Bull World Health Organ 96:414-422D","journal-title":"Bull World Health Organ"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-026-07537-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-026-07537-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-026-07537-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:02:50Z","timestamp":1790190170000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-026-07537-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":266,"alternative-id":["7537"],"URL":"https:\/\/doi.org\/10.1007\/s00467-026-07537-7","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"assertion":[{"value":"28 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}